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Electronic Health Records (EHR) containing large amount of patient data present both 
opportunities and challenges to industry, policy makers, and researchers. Data-driven healthcare 
utilizing big data in EHR has the potential to revolutionize care delivery while reducing costs. 
However, for researchers, policymakers, and practitioners to take full advantage of the benefits 
that electronic records can provide, several challenges must be addressed: 1) Extraction and coding 
methods for EHR data must be strategically designed to address issues of data quantity, quality, 
and patient confidentiality; 2) Standardization of clinical terminologies is essential in facilitating 
interoperability among EHR systems and allows for multi-site comparative effectiveness studies; 
3) Effective methods for mining longitudinal health data common in the EHR are critical for 
revealing disease progression, treatment patterns, and patient similarities, all of which play 
important role in clinical decision support and treatment improvement; 4) Advanced machine 
learning techniques are necessary for early detection and prognosis of disease and identifying 
critical factors that impact patient outcome and; 5) Practical intervention strategies must be 
developed to address healthcare disparity in rural and remote areas with lack of resources and 
access. This thesis focuses on these five issues by developing a systematic analytic pipeline for 
big data in healthcare. Specifically, innovative strategies are developed for information extraction, 
clinical terminology mapping, time-series mining and clustering, feature selection and 
discriminatory modeling. Finally, practical implementation methods for telehealth services are 




1. CHAPTER I 
INTRODUCTION 
1.1 OVERVIEW 
Electronic health record (EHR) plays an important role in advancing clinical and operational 
processes. Although early clinical medical records first appeared in 1600 BC, it was not until 1900 
that it was put into regular use [1]. The launch of the 10-year-effort to create a national electronic 
medical record system by the United State government in 2004 helped fuel its rapid adoption and 
medical advance [2]. As of 2015, 80 percent of U.S. hospitals had adopted a basic electronic health 
record keeping system [3]. The value of EHR data is increasingly recognized by healthcare 
organization and government. Its utilizations significantly changed the patient-clinic interaction 
process [1]. 
 For researchers, policymakers, and practitioners to take full advantage of the benefits that 
electronic records can provide, critical preparation steps including extracting relevant information 
from the EHR database [4], de-identifying and encrypting Protected Health Information (PHI) [5], 
and standardizing heterogeneous data [6] must be optimized. Analysis of big data require advanced 
Artificial Intelligence. Machine learning algorithms applied to big data in healthcare can identify 
favorable actions, predict risks, mortality, and length of stay. It is also part of a growing trend 
towards personalized, predictive medicine. EHR also offers access to longitudinal data including 
laboratory tests, prescriptions, and vital signs recorded during the delivery care, which can provide 
insights to disease progression and treatment outcome. These data records form unevenly spaced 
time series, rendering them difficult to analyze and understand with existing algorithms. 
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 Knowledge discovered from clinical data should be effectively transformed into practical 
implementations for multiple sites. Despite advances in communication technologies, many rural 
and remote areas still lack healthcare staff and services. Telehealth helps eliminate distance 
barriers and improve access to medical services that would often not be consistently available in 
distant rural communities. However, due to compounding challenges in confidentiality, technical 
difficulties, physician licensing, and reimbursement, it remains a promising but underdeveloped 
area of service. 
1.2 CONTRIBUTION OF THIS THESIS 
The work presented in this thesis makes several contributions to information extraction, knowledge 
discovery, and practical implementation strategies using EHR and other clinical big data: 
• An information extraction and concept mining framework for structured and unstructured 
data within the EHR is developed. Highly efficient queries are designed to identify and 
extract datasets with comprehensive coverage of target patient cohorts. An end-to-end 
pipeline is developed for extracting and consolidating key clinical features from 
unstructured narrative documents. 
• Multi-site heterogeneous EHR data are standardized via an automated mapping system, 
which links raw phrases and codes recorded in various clinical terminology and coding 
systems to Systematized Nomenclature of Medicine -- Clinical Terms (SNOMED-CT) 
concepts. 
• Techniques are introduced to extract knowledge from longitudinal clinical data in the form 
of time series. Specifically, univariate and multivariate time series clustering approaches 
are developed to characterize patient disease severity and recovery progress using 
laboratory and vitals recorded during delivery of care. 
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• Discriminatory features that inform optimized decisions during the treatment of diabetes, 
prostate cancer, and cardiovascular disease are identified with various state-of-art 
supervised learning algorithms. 
• A p-median facility location problem is formulated to set up telehealth sites to efficiently 
serve the rural communities. A prototypical design of a low-cost remote patient monitoring 
device that supports remote care management, secure communication, and monitoring of 
disease conditions is developed and its feasibility is evaluated using a Return of Investment 
(ROI) analysis.  
1.3 STRUCTURE OF THIS THESIS 
Chapter 2 provides the background knowledge of many existing technologies that provide the 
foundation for this dissertation. The concept of Named Entity Recognition (NER) and Clinical 
Terminology Systems, various distance metrics and clustering algorithms for time series, and 
supervised learning techniques are introduced. Challenges associated with healthcare disparity are 
presented, and the significance of this work is described.  
 Chapter 3 introduces the design and implementation of an efficient and comprehensive data 
extraction methods from epic EHR database. By designing efficient queries to extract data 
covering all aspects of patient information (i.e. demographics, diagnosis, laboratory and surgical 
procedures, medications, clinical notes, etc.), and developing a pipeline for identifying and 
extracting key clinical concepts from unstructured narrative notes, big data are explored with a 
holistic approach. 
 Chapter 4 develops an effective concept standardization process among the multitude of 
available clinical terminologies to facilitate sharing and exchange of healthcare information. An 
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automated pipeline is created to streamline the mapping process so that it can be easily adapted 
and applied to other EHR systems and establish data interoperability for quality care delivery and 
coordination among multiple healthcare sites. 
 Chapter 5 advances unsupervised learning algorithms for characterizing patient treatment 
outcomes based on longitudinal data. Challenges associated with mining laboratory and vitals data 
are presented and addressed. By utilizing existing similarity metrics and clustering algorithms, a 
new approach is developed to cluster irregular (unevenly spaced, with unequal lengths) 
multivariate time series (MTS).. 
 Chapter 6 compares and advances supervised learning methods to predict treatment 
outcome and identify discriminatory features for clinical practice and outcome improvement. 
Challenges associated with feature representation, feature selection, and imbalanced data in 
machine learning tasks are addressed. 
 Chapter 7 explores current status of and challenges in telehealth and design intervention 
methods to improve rural health access. A p-median facility location problem is formulated to 
identify optimal locations for setting up telehealth sites to efficiently serve the rural communities. 
A low-cost remote patient monitoring device that supports remote care management, secure 
communication, and monitoring of disease conditions is designed, and its practicality is evaluated 
through a Return of Investment (ROI) analysis.   
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2. CHAPTER II 
BACKGROUND AND SIGNIFICANCE 
Many information extraction techniques have been applied to the clinical domain. These 
techniques have developed from simple pattern matching, semantic-based, to more complex 
machine learning-based approaches. However, understanding unstructured clinical text remains a 
big challenge. Various clinical terminology systems have been developed to address the issue of 
“Variety”—one of the four “V”s that define big data. Both integrative and specialized terminology 
systems play important roles in promoting the interoperability of clinical data. 
 Knowledge learned from volumes of EHR data have proven valuable in many ways—
optimizing processes, personalizing treatment, informing decisions, improving patient experiences, 
and reducing costs. Both supervised and unsupervised machine learning algorithms have great 
utility in analysis of EHR. 
 Practical implementation guidelines and strategies have been developed to address 
healthcare disparity but have met many hurdles due to the sensitivity of protected patient health 
information, technical difficulties, and policy issues. Telehealth services and remote patient 
monitoring technologies have started to transform traditional healthcare delivery and improve 
patients’ quality of life in underserved areas. 
 This chapter covers established techniques and prominent challenges in each of these areas 
and identifies many gaps that need to be addressed. 
2.1 INFORMATION EXTRACTION AND PHI ENCRYPTION 
It is challenging to establish an efficient data extraction schema for EHR due to the complexity of 
data and lack of data standards. A common task in EHR is case detection – identifying a cohort of 
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patients with a certain condition or symptom. Coded data such as International Classification of 
Disease (ICD) codes are often not sufficient or accurate [7, 8]. Informatics approaches combining 
structured EHR data with narrative text data achieve better performance [9, 10]. Key clinical items 
can be extracted from narrative texts with simple methods such as pattern matching using regular 
expression [11-13], full or partial parsing based on morpho-semantems [14, 15], and syntactic and 
semantic analysis [16, 17]. Recently, more complex statistical and rule-based machine learning 
approaches [18, 19] have been developed to tackle this challenge. Biomedical Named Entity 
Recognition (NER) – the “task of identifying words and phrases in free text that belong to certain 
classes of interest” [20], allows users to identify key clinical concepts such as physician visits, 
referrals, dietary management, and suspected problems normally not present in structured data 
tables. Three main approaches have been used to accomplish this task: rule / lexicon-based [21, 
22], supervised learning [23-25], and hybrid Long-Short Term Memory (LSTM) – Conditional 
Random Fields (CRF) [26, 27].  
 Negation detection,  which identifies the negative sense of a concept, is another essential 
task accompanying NER, since the presence of negations can yield false-positive detections 
because medical personnel are trained to include pertinent negatives in their reports [28]. It has 
been achieved through rule-based / syntactic parsing [29-31] and machine learning [32-34] 
approaches. 
 Once patient information is extracted, data security and confidentiality must be ensured 
through de-identification steps. According to Health Insurance Portability and Accountability Act 
(HIPAA), patients’ Protected Health Information (PHI) must be de-identified or anonymized for 
commercial and research interest. PHI exists in both structured and unstructured clinical records 
[35]. This includes patient names, addresses, phone numbers, etc. Manual and rule-based or 
7 
 
lexicon-based methods have been used to achieve PHI de-identification [36-38], but they are 
extremely time-consuming and can be inaccurate. Machine learning approaches have also been 
developed [39-41]. However, due to the complexity of data schemas and the heterogeneity of data 
structures, it is very challenging to detect PHI with high sensitivity. 
2.2 CLINICAL DATA INTEROPERABILITY AND TERMINOLOGY MAPPING 
Data from EHR and other forms of clinical and biomedical data can reveal critical variables that 
impact treatment outcomes and inform allocation of limited time and resources, allowing 
physicians to provide evidence-based treatment plans that suit the needs of individual patient. On 
a larger scale, realistically modifiable social determinants of health that will improve community 
health can potentially be discovered and addressed. Tackling the problem of data heterogeneity is 
essential for conducting predictive analytics using artificial intelligence. Many clinical records in 
the EHR adhere to different terminology systems and can cause problems such as data redundancy 
and inconsistency, exacerbating the issue of “curse of dimensionality” associated with big data, 
and hindering the performance of automated machine learning models. 
 Standardized clinical terminologies are essential in facilitating interoperability among 
EHR systems. They allow seamless sharing and exchange of healthcare information for quality 
care delivery and coordination among multiple sites. However, the volume and number of 
available clinical terminologies are large and are expanding. Due to the increase in medical 
knowledge, and the continued development of more advanced computer systems, the usage of 
medical terminologies has extended beyond diagnostic classification [3]. The Systematized 
Nomenclature of Medicine – Clinical Terms (SNOMED-CT) is the most comprehensive 
healthcare terminology and is widely implemented and used in clinical settings [42-47]. It provides 
foundation for patient-practitioner interactions, laboratory testing and reporting, clinical problems, 
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pharmaceutical ingredients, medical and surgical procedures [48]. When complemented with other 
vocabularies (e.g. LOINC), SNOMED-CT can be used to build the enterprise reference 
terminology of a healthcare organization [48]. The Unified Medical System (UMLS) is a 
terminology integration system developed by the US national library of medicine (NLM) to 
promote the interoperability of systems and mapping between the multitude of available clinical 
terminologies [49]. UMLS includes tools for customizing the Metathesaurus (e.g. filter terms by 
type), for generating lexical variants of concept names (lvg), and for extracting UMLS concepts 
from text (MetaMap) [49-51]. The Metathesaurus is a large vocabulary database built from 
electronic versions of various thesauri, classifications, code sets, and lists of controlled terms used 
in patient care, health services billing, public health statistics, indexing and cataloging biomedical 
literature, and/or basic, clinical, and health services research [52]. These are referred to as the 
"source vocabularies" of the Metathesaurus [52]. It is used in our study to links alternative names 
and views of the same concept from various ontology systems. The Logical Observation Identifier 
Names and Codes (LOINC) database provides a universal code system for reporting laboratory 
and other clinical observations and has been implemented as the standard terminology system for 
laboratory test / radiology results [53-56]. RxNorm provides normalized names for clinical drugs 
and links its names to many of the drug vocabularies commonly used in pharmacy management 
and drug interaction software [57, 58]. Both LOINC and RxNorm are source vocabularies of 
UMLS and can be linked to SNOMED-CT via UMLS [59-61]. Clinical procedure coding systems 
including the Current Procedural Terminology (CPT), HCPCS Version of Current Procedural 
Terminology (HCPT), and Healthcare Common Procedure Coding System (HCPCS) are also 
source vocabularies of UMLS and can be linked to SNOMED-CT via UMLS [59]. UMLS also 
contains mapping tables between SNOMED-CT and International Classification of Diseases, 
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Ninth Revision (ICD-9) / Tenth Revision (ICD-10), which are used for coding diagnosed problems 
[62]. 
 Many systems have been developed to map heterogeneous terminologies to support 
communication and semantic interoperability between healthcare centers. STRIDE mapped 
RxNorm concepts to the SNOMED-CT hierarchy and used the RxNorm relationships in UMLS to 
link pharmacy data from two EHR sources in the Stanford University Medical Center [60]. Carlo 
et al. classified ICD-9 diagnoses from unstructured discharge summaries using mapping tables in 
UMLS [63]. Patel and Cimino used the existing linkages in UMLS to predict new potential 
terminological relationships [64]. Many of these studies only focus on one type of standardized 
concept. In [6], clinical concepts describing diagnosis, laboratory, and medications were 
standardized by a concept mapping system which links these concepts to the SNOMED-CT 
terminologies. These mapped SNOMED-CT concepts were generalized into level 2 nodes for 
medications and diagnoses and level 3 nodes for laboratories based on the SNOMED-CT concept 
tree. However, it is much more challenging to standardize clinical procedure concepts and codes 
due to their comprehensive coverage of products, supplies, services, and surgical and diagnostic 
procedures. 
2.3 UNSUPERVISED LEARNING FOR CLINICAL DATA 
Analyzing longitudinal clinical data recorded during care delivery is challenging due to their 
incompleteness and non-uniformness. Identification of subgroups of patients who experience 
symptoms with greater or lesser severity [65] or respond to treatment procedures differently may 
reveal critical risk or treatment factors that impact patient outcome. Laboratory and vitals 
measurements before, during, and after treatment may act as markers of disease severity [66] and 
characterize recovery process. Uncovering patient clusters also have prognostic significance – by 
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constructing cluster-based mortality prediction models, one can achieve superior performance 
when compared to treating all patient episodes as a single group [67]. However, laboratory and 
vitals in the form of time series often exhibit different lengths and frequencies due to different 
syndromes and treatment schedules for different patients. Thus, conventional clustering algorithms 
aiming to identify patient subgroups cannot be applied directly. Pre-processing methods such as 
interpolation [68, 69] and resampling [70] can normalize time series data, allowing clustering 
approaches such as K-means [71] to be used. Alternatively, clustering algorithms have been 
customized for variable-length time series. These algorithms can be characterized into time-based 
[72-75], shape-based [76-78], and structural-based [79, 80]. They utilize a variety of similarity 
(distance) measures such as Dynamic Time Warping (DTW) [78], Longest Common Subsequence 
(LCSS) [81], Cosine Wavelets [82], Edit distance with Real Penalty (ERP) [83], Global Alignment 
Kernel (GAK) [84], and Time-Warp Edit Distance (TWED) [76]. 
 While some disease severity can be characterized by a single time series per patient — for 
example — serum cholesterol levels can be used to characterize conditions of patients with 
hyperlipidemia [66], others can be better defined by multiple laboratory measurement time series. 
For instance, systolic blood pressure and diastolic blood pressure should be both considered for 
patients with hypertension. Clustering approaches for such Multivariate Time Series (MTS) [85] 
are limited. Existing PCA-based [86], Hidden Markov Model (HMM)-based , partition-based [87], 
and model-based approaches [88, 89] have been applied to a variety of fields including chemistry 
and manufacturing, but have not been utilized in clinical settings. This is likely due to the 
irregularity of clinical time series. As far as we are concerned, clustering approaches have not been 
developed for MTS with irregular intervals and unequal lengths. These MTS will be referred to as 
“irregular MTS” throughout this thesis. 
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2.4 SUPERVISED LEARNING FOR CLINICAL DATA 
The use of predictive modeling for clinical decision making has great value in improving outcomes, 
enhancing patients’ experiences, and reducing health care costs [90]. The discriminatory features 
identified, and the criteria developed via machine learning framework can be used to design and 
optimize evidence-based treatment plans and to disseminate such knowledge through “rapid 
learning” across multiple sites [6].  
 To utilize existing machine learning frameworks, one must first transform clinical variables 
into suitable forms of input features, or potential predictor variables. Continuous variables 
including laboratory measurement, vital sign, and drug dosage can be flattened into mean, median, 
or most-recent-value representations [91-93]. They can also be discretized, clustered, or binarized 
into “Yes/No” variables [91, 92, 94-96]. Discrete variables including procedure, diagnosis, and 
prescription can be represented as binary/categorical features [91, 94-96]. In some cases, most 
recent diagnosis or procedure are isolated as nominal input features [92, 94, 96]. 
 Many state-of-the-art supervised learning algorithms have been utilized in the clinical 
setting. Among them, Support Vector Machine (SVM) [92, 94, 95, 97-100], Tree-based and 
Ensemble methods [91, 92, 94, 95, 98, 99], Logistic Regression [91, 92, 95, 96, 100], Naïve Bayes 
[94, 98], and Artificial Neural Network [97] are the most commonly used in classification tasks. 
One crucial problem that often rises in the clinical setting is imbalanced datasets, especially when 
the goal is to maximize the machine learning model’s ability to distinguish the minority class [101]. 
Strategies to address this concern include resampling the dataset [101-103] and modifying the 
classification algorithm [101]. 
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 Feature selection algorithms are essential for narrowing down the list of discriminatory 
factors in supervised learning models. Reducing the number of predictor variables not only results 
in faster computations, but also allow for implementation of practical clinical guidelines. The most 
commonly used methods such as correlation-based feature selection [94, 96], feature importance 
from tree-based classifiers [91, 92, 97], and Lasso [92, 104, 105] have all shown successes in the 
clinical setting. Recently, wrapper-based approaches have also gained interests [106, 107]. They 
use feature selection algorithms to search through the space of attribute subsets with cross-
validation accuracy from the classification module as a measure of goodness [107]. 
2.5 TELEHEALTH AND REMOTE PATIENT MONITORING 
Telemedicine is the use of electronic information and communication technologies to provide and 
support healthcare services to individuals who are some distance from the health care provider 
[108]. Telemedicine has a growing variety of applications such as telesurgery, psychiatric 
consultation, and home monitoring of patients [108]. Many health organizations have gained 
interests in adopting telemedicine technologies to support member physicians’ practices or to 
extend existing services [109]. The use of telemedicine has been rapidly integrated into hospitals 
[110], home health services [111],  and specialty care departments [111, 112].There are over 360 
telemedicine programs in the United States and 450 worldwide [113]. These programs most 
commonly serve those who reside in rural areas, the elderly, and veterans, in many medical 
specialties [114]. Telemedicine has proven to have many benefits upon implementation. Patients 
living in rural and isolated regions gain more convenient access to treatment and consultations 
when they can be conducted online, which eliminates transportation costs and reduce absence of 
work. Remote patient monitoring achieved through mobile and sensor technologies can improve 
medical service quality by providing more affordable, accessible, and timely care [115]. The 
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possible transmission of infectious diseases can also be minimized if patients remain at home in 
more controllable conditions. 
 Although many telemedicine intervention programs have been successful, adoption of 
telemedicine and the level of engagement and services provided across healthcare facilities remain 
uneven and far from optimal. Compounding the challenges are patient confidentiality and privacy, 
technical difficulties, licensure issues, and economy and quality of care for reimbursement. There 
remains an enormous opportunity to expand telemedicine service to provide more timely 
communication and consultation to patients, reduce the face-to-face demand, and the cost of 
delivery. 
 Confidentiality and privacy are major concerns when patients’ personal information is 
exchanged virtually. Breach of personal health information (PHI) can occur on unsecured network, 
or through illegal access to unencrypted hardware by third parties [116]. This could have 
potentially destructive consequences such as patient identity disclosure, embarrassment, privacy 
violation, or integrity violation [117].  
 Technically challenged staffs and patients create another hurdle to telemedicine practice 
[116]. Lack of computer literacy and the unwillingness to accept new technology are prevalent 
among the older generations. In many developing countries, high-speed internet, which is 
necessary for video conferencing and high-resolution image transmission, is also challenging to 
implement [118]. 
 Another barrier to telemedicine is that physicians are required to obtain licenses from each 
state in which their current or potential patients are, or maybe, located [119]. Although some states 
provide expedite multistate licensing [120], these measures are still insufficient for telemedicine 
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to expand its impact. It is impractical and expensive for healthcare providers and organizations to 
obtain medical licenses in all 50 states for telemedicine practice under the current regulations [121]. 
The Interstate Medical Licensure Compact is an attempt to alleviate the licensing burden of 
physicians by enacting legislations that promote the expansion of telemedicine without losing 
control of the regulatory aspects of telemedicine care [122]. It allows the involved states to 
confront shared needs and issues collectively [122]. 
 Reimbursement issues also present a huge challenge for sustainable telemedicine programs. 
Medical consultations provided over the telephone are usually not reimbursed by private insurers 
due to concerns including the abuse of telemedicine services leading to diminished resources in 
already underserved areas [123]. Only private payers in some states such as Georgia Blue Cross 
and Blue Shield have guidelines under which telemedical consultations can be reimbursed [123]. 
In 1997, Medicare started reimbursing for some telemedical services delivered via live interactive 
video and expanded coverage further in 2000 [124]. Although Medicare reimbursement policy 
changed little since then, state policies have developed significantly, increasing the number of 
covered services or payers for telemedicine programs [124]. However, this does not solve the 
problems for rural areas, which have greater shortages of primary and specialty health care 
providers, increased prevalence of chronic disease, and a larger population of individuals who rely 
on Medicare and Medicaid [125]. 
 Since 2009, patient-centered medical homes have been piloted to create a professional care 
team for coordinated healthcare services to engender a health-friendly environment [5]. Another 
emerging approach to reducing costs and providing patients with more accessible care is through 
remote monitoring systems (RMS), which connect patients to providers or health coaches. They 
can be tailored for the elderly, for the chronically ill, or for patients recently discharged. They can 
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be used in rural areas where timely and proper healthcare access is limited. RMS allow patients to 
have more frequent interaction with healthcare providers and expand the reach and influence of 
healthcare providers to patients between regular office visits. They facilitate proactive patient-
centered medical care and advice that is personalized and continuous. They can also be used for 
tracking patient health and medication compliance. With proper use, there is a potential that RMS 
can significantly improve quality of services, maintain proactive patient health engagement, while 
reducing costs. RMS technologies have proven to improve adherence to treatment requirements 
due to the sense of novelty they provide [126]. Since telehealth has not been as widely adopted 
and implemented as anticipated due to the challenges listed above, there is a demand for low-cost 
RMS, especially for low-income patient groups and for the rural population.  
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3. CHAPTER III 
INFORMATION EXTRACTION AND CONCEPT MINING FROM ELECTRONIC 
HEALTH RECORDS 
3.1 INTRODUCTION 
Features of big data revolution can be characterized by the HACE theorem [127]. Big Data is 
large-volume, heterogeneous, and has autonomous sources with distributed and decentralized 
control. In addition, there are complex and evolving relationships among data [127]. Big data is 
the enormous mixture of data in various formats and is thus heterogeneous, which becomes an 
obstacle when aggregating data in different formats and types [127]. In the clinical context, 
heterogeneous data result from multi-provider, multi-sites, and multi-terminologies. The 
autonomous characteristic of big data means that each data source can generate and collect 
information with no centralized control [127]. Autonomous health information systems have and 
will continue to play important roles in the clinical setting. With the continuous increase of big 
data, complexity develops in a high speed [127]. Big data in the EHR is extremely complex due to 
the scope of information they contain. Finally, big data is always evolving, rendering old-fashion 
data structure and analytical methodologies insufficient [127]. Clinical big data continues to evolve 
as it is essential to track the long-term development of patients. Furthermore, medical 
terminologies are also becoming more and more encompassing and EHR systems are constantly 
evolving to match the standards. 
 Kaiser Permanente (KP) uses the Clarity module to transform data from EPIC’s operational 
database into a relational form for reporting. Clarity database from the KP’s HealthConnect EHR 
system stores patient data in over 7,000 tables with over 60,000 columns and updates daily [128]. 
The EPIC Clarity database has recently been imported to Oracle Exadata for performance 
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improvement. Structured Query Language (SQL) written in Oracle SQL Developer is the primary 
programming language used to access the database. 
 The EPIC Clarity database contains both structured and unstructured data relating to patient 
demographics, medical history, current and past diagnoses, medications, billings, laboratory orders 
and results, and clinical notes. Fully extracting the data necessary to understand a cohort of patients 
is challenging due to the complexity of the database structure and the variety of data entries. In 
this chapter, we attempt to develop an information extraction framework which is holistic, efficient, 
accurate, and handles large bodies of unstructured narrative clinical notes. 
3.2 MATERIAL AND METHODS 
3.2.1 Extract Patient Cohort Characterized by Disease or Symptoms 
To extract patient data with certain disease or symptoms, we first utilize the ICD-9 / ICD-10 
diagnosis codes. A Patient ID is selected from the problem list table if its corresponding record 
contains the target diagnosis code(s). In many cases, however, diagnosis codes are not well-
maintained, so it is necessary to utilize billing information, laboratory measurement data or 
narratives in clinical notes for more accurate case detection. This can be done using semantic 
matching of key terms describing medical conditions. The extracted patient IDs are then used to 
link to the other data tables to extract the relevant information.  
Table 3.1 lists the types and coverages of information extracted. Although most demographics, 
medications, billings, procedures, and co-existing conditions can be found directly from structured 
data tables, encounter-level data containing physician visits and referrals, dietary management, 





TABLE 3.1 DATA COVERAGE BY SOURCE TABLES. 
Coverage Source database tables 
Encounter-level data Encounter / Clinical notes tables 
Medications data Medications table 
Billing information Billings table 
Procedures Billings / Clinical notes tables 
Clinical notes Clinical notes table 
Problem list (co-existing conditions) Problem list / Billings/ Clinical notes tables 
Laboratory Order table / Clinical notes table 
 
3.2.2 Extract Patient Cohort Characterized by Treatment Features 
To extract patient data with certain treatment features (i.e. procedures, prescriptions, laboratory 
measurements), all the possible vocabularies that represent the treatment features must first be 
identified. These vocabularies are compiled into a list and are used to index the billings / laboratory 
/ medications tables to select the target patient IDs. Alternatively, regular expressions can be used 
to represent groups of vocabularies to create more succinct queries. 
3.2.3 Table Partitioning and Temporary Views 
In many data extraction tasks, the targeted patient cohort contains millions of patient records 
amounting to terabytes of data. In such cases, table partitions are created to retrieve data by chunks 
and reduce local storage loads. Temporary views are used to reduce server loads. 
3.2.4 PHI Encryption for Structured Data and Narrative Texts 
The SHA-256 Cryptographic Hash Algorithm is used to encrypt Patient IDs contained in every 
data record. For unstructured free-text data, the transition-based parsing model implemented in the 
Python spaCy package [129] is applied to detect and de-identify PHI in clinical notes. Entities 
including “PERSON”, “NORP”, “ORG”, and “GPE” are identified. These entities cover patient 
names, nationalities, organizations, and addresses. In addition, a regular expression-based filter is 
leveraged to replace telephone numbers. 
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3.2.5 Information Extraction from Narrative Clinical Texts 
An end-to-end “pipeline” (software from EPIC Systems coded to process data into a more usable 
form) is developed for extracting key clinical features from narrative documents. These features 
are then filtered by negation detection and remaining features are mapped to standardized 
SNOMED-CT terminology. Figure 3.1 shows the feature extraction pipeline from clinical text. 
The content summarization module is implemented based on the TextRank algorithm [130]. The 
CLiNER concept recognition model [26] is leveraged to extract key clinical features including 
problems, procedures, and tests. An improved Negex [29] algorithm is then used to filter features 
within a negated context. This portion of the pipeline has been implemented as a secure in-house 
web application where the user is allowed to upload files containing narrative clinical notes and 
obtain extracted key clinical features along with their contexts. 
 From here, two approaches can be taken: 1) utilize MetaMap to map the extracted features 
to the SNOMED-CT terminology system and filter out features that are not mapped. The 
hierarchical structure of SNOMED-CT and MetaMap are utilized to remove general concepts (e.g. 
“Body structure”, “Clinical finding”, “Biological agent”) that are situated at the top two levels in 
the SNOMED-CT concept tree; 2) utilize the terminology mapping system developed in chapter 4 
to directly map these concepts to SNOMED-CT. These standardized concepts can be consolidated 





Figure 3.1 Treatment feature extraction from clinical texts. 
3.3 RESULTS 
In this section, we demonstrate the use of the EHR information extraction methods for two 
different patient cohorts: prostate cancer and chronic kidney diseases (CKD). 
3.3.1 Patients with Prostate Cancer 
Prostate cancer is the most frequently diagnosed cancer in 105 countries and the fifth leading cause 
of cancer death in men [131]. It is estimated that there will be 174,650 new cases of prostate cancer 
in the US in 2019 and an associated 31,620 deaths [132]. Early prostate cancer detection has been 
achieved through prostate‐specific antigen (PSA) testing and biopsy of tissue removed during 
prostatectomy or at autopsy [131]. However, PSA testing has been questioned for its accuracy in 
detecting prostate cancer [133] and for the high cost it carries in terms of overdiagnosis and 
overtreatment [134-137]. Through mathematical modelling, [138] concluded that under the 
assumption that stage shift implies survival shift–which motivates early detection of cancer, PSA 




 EHR provides long-term tracking of patient PSA testing results. These longitudinal data 
can be extracted given the lab component IDs or names corresponding to the testing procedure. 
The rate of increase in PSA level, often represented using PSA doubling time or PSA velocity, has 
been widely used in the management of prostate cancer [139]. Trajectories of post-treatment PSA 
is associated with cancer mortality [140]. In this thesis, a clustering technique is developed and 
applied to identify patient subgroups with distinct post-treatment PSA trajectories. 
 The extracted dataset from EPIC EHR covers 98,806 patients with the ICD-9 code 790.93 
or the ICD-10 code 97.20, “elevated prostate specific antigen (PSA)”. This dataset spans the years 
1997-2018 and is composed of patient-level data (70Mb), problem lists (384Mb), medications 
(7.3Gb), billings (167Mb), laboratory orders (10Gb), and clinical notes (46.1Gb), totaling 64.02 
Gigabytes. Patient IDs were successfully encrypted using SHA-256 encryption. PHI including 
patient names, addresses, institutions, age, phone numbers, and email addresses were detected and 
encrypted into dummy tokens. 
 The clinical concept extraction system was applied on a subset of patients treated with 
radioactive seed implants. An additional 2,194 standardized clinical features were extracted from 
their clinical notes, including “Chronic pain syndrome”, “Placement of stent”, “Nerve conduction 
testing”, “Vascular Calcification”, “Overweight”, “Obstructive sleep apnea syndrome”, 
“Neoplasm, metastatic”, and “Lithotripsy”, etc. 
 Patient PSA laboratory test results were used as indicators of disease severity. PSA records 
were retrieved by the following method: 1) component IDs for lab records matching the query 
string “%PSA%” were retrieved; 2) PSA-irrelevant lab components were discarded, leaving 10 
unique component IDs corresponding to “PSA-screening”, “PSA-monitoring”, “PSA”, “PSA 
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FREE”, “PSA % FREE”, “PSA, external result”, “PSA, MHS”, “PSA with reflex FPSA, external 
result”, “PSA, screening”, and “PSA, cancer monitoring”; 3) “PSA FREE” and “PSA % FREE” 
were removed from the list of candidate components since free PSA is reported as a percentage of 
the total that is not protein bound, i.e., free. The higher the free PSA, the lower the likelihood of 
cancer; 4) PSA lab records were then retrieved by patient IDs and the filtered component IDs; 5) 
Missing, erroneous, and duplicated records were removed, and the remaining records were sorted 
by date and transformed into time series format for each patient. 
3.3.2 Patients with Chronic Kidney Disease (CKD) 
Kidney is an important organ of human body – filtering blood, removing waste, balancing fluid, 
and controlling the level of electrolytes. Chronic Kidney Disease (CKD) is becoming more 
prevalent at a rapid speed across the world. 
 CKD can be divided into 5 stages based on estimated glomerular filtration rate (eGFR) 
measurement. Early diagnosis of CKD prevents patients from regressing into late-stage CKD 
which causes serious complications. Late-stage CKD can lead to end-stage renal disease (ESRD) 
and cardiovascular disease (CVD), which steeply increase patient pain and economic burden. 
However, the gradual loss of kidney function is difficult to diagnose due to the absence of direct 
evidence from clinical trials [141]. Hence frequent and regular measurements of serum 
creatinine—used to calculate eGFR—is essential for evaluating changes in renal functions. 
Identifying trends in eGFR is more important than one-off readings, as suggested by the Renal 
Association, “a progressive fall in eGFR across serial measurements is more concerning than 
stable readings which don’t change over time” [142] 
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 EHR provides a possibility for health care organization to identify early-stage CKD. Lenart 
et al. developed clustering techniques to detect progression of CKD [143]. K-medoids clustering 
was applied on patients’ routine measurements and lab tests such as blood pressure, body mass 
index, Hemoglobin A1c (HbAlc), triglycerides and high-density lipid cholesterol [143]. The 
Cluster Progression Score (CPS) was designed to measure the patients’ relative health status [143].  
This clustering process can help health care organization diagnose early stage CKD by monitoring 
the recorded lab measurements. 
 The extracted dataset from EPIC EHR covers 33,303 patients with the ICD-9 code starting 
with “585” or ICD-10 code starting with “N18”, both referring to “Chronic Kidney Disease”. This 
dataset spans the years 1997-2018 and is composed of patient-level data (24Mb), problem lists 
(288Mb), medications (6.74Gb), billings (1.90Gb), laboratory orders (8.66Gb), and clinical notes 
(18.55 Gb), totaling 36.16 Gigabytes. Patient IDs were successfully encrypted using SHA-256 
encryption. PHI including patient names, addresses, institutions, age, phone numbers, and email 
addresses were detected and encrypted into dummy tokens. 
 Patient eGFR laboratory test results were used as indications of disease progression. eGFR 
records were retrieved by the following method: 1) component IDs for lab records matching the 
query string “%eGFR%” or “%GLOMERULAR FILTRATION RATE%” were retrieved; 2) 
Irrelevant lab components were discarded, leaving 16 unique component IDs. eGFR records 
matching these component IDs are examined it was discovered that only records corresponding to 
two component IDs “12122727” and “12122728” were well-maintained in the EHR. 3) eGFR lab 
records were then retrieved by patient IDs and these two component IDs. 4) Missing, erroneous, 
and duplicated records were removed, and the remaining records were sorted by date and 




In this chapter, a comprehensive information extraction pipeline for EPIC-based EHR system is 
designed. This pipeline is capable of effectively and efficiently extracting structured data from 
interlinked data tables. It can also identify key clinical concepts including problems, procedures, 
and tests along with their word sense. These concepts can be further standardized and generalized 
using the SNOMED-CT terminology system. This pipeline is applied to two cohorts of patients – 
those with prostate cancer and chronic kidney diseases, to generate tabularized data files with 
standardized terminologies and reduced feature dimensions. These data files can be directly 
provided as input into machine learning algorithms for further knowledge discovery. 
 With minor modifications to some processes in the pipeline, it can be applied to similar 
large EHR datasets and for other patient cohorts. These modifications might include: 1) 
redesigning SQL queries by modifying diagnosis codes when extracting patient ID list to 
accommodate different target cohorts; 2) modifying SQL queries to extract additional data from 
target disease-specific tables; 3) reidentifying new motifs through expert recommendation and/or 
manual exploration of free-text data and redesigning new regular expressions for pattern-based 
feature extraction. 
 Through the design and implementation of this pipeline, many big data challenges 
including volume, variety, veracity, and value are addressed. This results in a highly robust, 
efficient, and customizable pipeline that can be easily applied to current EHR databases to fulfil 
their potential in both academic and clinical research.  
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4. CHAPTER IV 
ESTABLISH DATA INTEROPERABILITY WITH MEDICAL TERMINOLOGY 
MAPPING 
4.1 INTRODUCTION 
EHR data are recorded by different clinicians and different providers at various hospital sites. As 
a result, data heterogeneity becomes a major issue due to the significant practice variation in style 
of reporting, use of terminologies and descriptive content. These pose a huge challenge for 
understanding these already complicated data. Tackling the problem of data heterogeneity in the 
EHR is essential for conducting predictive analytics and discover knowledge. 
 To the best of our knowledge, integration of EHR data across hundreds of healthcare sites 
and millions of patients has not been attempted previously. Past studies have focused on inter-
terminology mapping between specific source vocabularies. In this chapter, a terminology 
mapping system is developed for an EHR covering 737 clinical sites and de-identified data for 
over 2.7 million patients with data collected from January 1990 to December 2012. This system 
establishes interoperability among these multi-site data by accurately mapping ICD-9 diagnosis 
codes and free text describing laboratory and medication terms to concise structured SNOMED-
CT medical concepts. This allows for shared characterization and hierarchical comparison of 
patient characteristics. This system is then extended to include the functionality of mapping 
CPT/HCPCS codes and free text describing clinical procedures to SNOMED-CT concepts, and an 
automated pipeline is developed to streamline the mapping process to allow easy adaptation to 
other EHR systems. 
4.2 MATERIAL AND METHODS 
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4.2.1 Dataset Description and Management 
This study utilizes EHR data of 2.7 million patients collected from 737 healthcare facilities. A 
relational database is first designed with Postgres 9.2.18 to store these data. Thirteen tables are 
created containing patient records pertaining to procedures, demographics, diagnosis codes, 
laboratory measurements and medications. Indexes are developed for each table to enable rapid 
search and table joins for data querying. The data size for indexes is an additional 11 GB, totaling 
27 GB for the entire database. It is labeled as the CCI-health database, where CCI stands for Care 
Coordination Institute. In the CCI-health database, 2.46 million patients are associated with a 
diagnosis, 1.89 million are associated with procedures, 1.33 million are associated with 
laboratories, and 955,000 are linked to medications [6]. 
4.2.2. Data Integration and Mapping to Standardized Medical Concept 
Laboratory and medication records are described with free text entries without unique codes for 
each entry. Since clinicians may describe identical treatments with many possible variations, it is 
essential to map entries to structured concepts without ambiguity. Overall 803 unique lab phrases 
and 9,755 medication phrases were extracted from the patient records. In this study, Metamap is 
used to map laboratory and medication terms to UMLS Metathesaurus terms. Laboratory and 
medication terms are then linked to LOINC and RxNorm terms respectively. This is done 
respectively using the UMLS MRCONSO and RXNCONSO tables. The final step is to map 
associated terms to concepts in the SNOMED-CT ontology. LOINC and RxNorm terms 
established from the CCI-health database are linked to SNOMED using the UMLS MRREL and 
RXNREL tables. In this implementation, for LOINC, only concepts that have the name “procedure” 
were returned from the MRREL table. For RxNorm, only concepts that have “has_form”, 
“has_ingredient”, and “has_tradename” relationships are returned from the RXNREL table.  When 
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medication entries in an EHR and a SNOMED concept are named completely differently, 
relationships can still be found due to rules such as tradenames and ingredients. Figure 4.1 and 
Figure 4.2 show the workflows for mapping laboratory and medication phrases to SNOMED-CT 
concepts. 
 
Figure 4.1. Mapping process for laboratory phrases to SNOMED-CT concepts. 
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 The CCI-health database employ ICD-9 codes for patient diagnoses [53]. This makes the 
mapping procedure to SNOMED-CT concepts slightly different from those designed for 
laboratories and medications. The ICD9CM_SNOMED_MAP table in UMLS can be used to map 
ICD-9 directly to SNOMED-CT concepts. However, this does not include all ICD-9 codes that are 
associated with patients in the CCI-health database. Metamap is then used to analyze the 
descriptions of the remaining ICD codes that are not found in the ICD9CM_SNOMED_MAP table 
and map them to UMLS Metathesaurus concepts. The MRCONSO table is then used to map the 
UMLS concepts to associated SNOMED-CT concepts. 
 
Figure 4.3. Mapping process for diagnosis ICD-9 codes to SNOMED-CT concepts. 
 Procedures are recorded in the EHR database using the Healthcare Common Procedure 
Coding System (HCPCS), which consists of two levels including the level I common Current 
Procedural Terminology (CPT) codes and Level II codes which identify products, supplies, and 
services not included in CPT [144]. Mapping procedures to SNOMED-CT requires a more holistic 
approach than that of the other concepts since HCPCS contains codes for clinical labs, medications, 
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and procedures/interventions [145]. Although HCPCS is one of the source vocabularies in the 
UMLS, many codes do not have direct matches to SNOMED-CT concepts. Therefore, the 
following mapping process is developed: first, concepts strings corresponding to the procedure 
codes are extracted from the MRCONSO table. Out of the 11,374 unique codes, 7,570 had one or 
more matches in the MRCONSO table. Secondly, MetaMap is used to identify one or more UMLS 
candidate concepts that are associated with these extracted concepts. Candidate concepts that had 
the highest evaluation score using MetaMap’s natural language processing are selected. Some of 
these UMLS concepts have corresponding Metathesaurus concepts that could be linked to 
SNOMED-CT concepts directly. For those UMLS concepts that do not have a direct mapping to 
SNOMED-CT, LOINC and RxNorm terms are used to link them to SNOMED-CT using MRREL 
and RXNREL tables. If a UMLS concept can be linked to both LOINC and RxNorm sources, the 
source with the higher matching score is selected. 
 
Figure 4.4. Mapping process for procedure codes to SNOMED-CT concepts. 
4.2.3 Automation of Mapping Process 
Although the mapping approaches for labs, medications, diagnoses, and procedures are different, 
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provided on how to set up the necessary knowledge databases and software, and how the developed 
scripts are leveraged to establish the mapping tables. 
 The Postgres 9.2.18 database is set up on a Red Hat Enterprise Linux Server release 7.3 
operating system. MetamorphoSys, the UMLS installation tool, is downloaded from the NLM 
website (2016AB release) and used to generate the UMLS data in the Rich Release Format (RRF) 
files. Database table creations scripts can be found inside the installation directory. The Postgres 
table and index creation scripts provided by UMLS are used to load the RRF files into the database. 
Metamap 2016 v2 binaries are downloaded from https://metamap.nlm.nih.gov/ and installed. After 
setting up the EHR database, the UMLS knowledge databases, and Metamap, a script is developed 
in Python 2.7.5 to streamline the mapping procedure. It is readily deployable after specifying the 
input file containing terms to be mapped, UMLS database access credentials, the path to Metamap 
binaries, and the mapping output database and output file names. The script will read, analyze, and 
store matching SNOMED-CT concepts to labs, medications, diagnoses, and procedures in the EHR 
for rapid retrieval and further expert evaluation. 
4.2.4 Refinement and Validation of Mapping Results 
SNOMED-CT provides a rich hierarchy enabling semantic distances between concepts to be 
measured by path distances. ANeo4j Graph Database is developed for the CCI-health data to 
rapidly compute common ancestor queries between the mapped SNOMED-CT terms. In our Neo4j 
Graph Database, tab-delimited files of all SNOMED concepts and relationships are exported from 
SNOMED CT Postgres relational database tables. The tab delimited files were then directly loaded 
into Neo4j community edition 2.0.0 using their batch inserter 
(http://docs.neo4j.org/chunked/milestone/batchinsert.html). This results in a SNOMED Graph 
Database that has many cycles. The cycles greatly impede graph operations such as returning all 
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paths between nodes. This issue is addressed by removing edges from these cycles to construct a 
directed acyclic graph (DAG). To select the proper edge that needs to be removed from each cycle, 
three different criteria are used: 1) maximum depth, 2) shortest path, and 3) fan-in count.  
Maximum depth is the maximum number of nodes between the current node and head node (root) 
of the ontological graph. Here the node with the Concept ID “138875005”, corresponding to the 
Concept Name “SNOMED CT Concept”, is chosen as the head node. In each cycle, edges whose 
source node has a smaller maximum depth than its target node is removed (Figure 4.5). 
Figure 4.5. Maximum Depth Criteria: S is the head node. In the cycle A->B->C->D->A, since A has a smaller 
maximum depth than B, and B has a smaller maximum depth than C, edges A->B and B->C will be removed. 
 Shortest path is the shortest distance (number of edges) from the current node to the head 
node. In cases where the maximum depth of all nodes in the cycles are equal, edges whose source 


























Figure 4.6. Shortest Path Criteria: S is the head node. In the cycle A->B->A, A and B has equal maximum 
depth. Since A has a shorter shortest path to S than B has, edge A->B will be removed. 
 Finally, if all nodes in the cycle have equal maximum depths and shortest paths, the Fan-
in count criteria is used. Fan-in count is the number of incoming edges to the current node in the 
cycle. Nodes with larger degrees of incoming nodes are expected to represent more generalized 
concepts. Therefore, edges whose source node has a larger fan-in count than its target node are 
removed (Figure 4.7).  
 
Figure 4.7. Fan-in Count Criteria: S is the head node. In the cycle A->B->A, A and B has equal maximum depth 
and shortest path. Since A has a larger fan-in count, edge A->B will be removed. 
These criteria are selected to reduce the likelihood of a node representing a more specific concept 
from becoming a parent of a node representing a more generalized concept in the final concept 
graph. 
 After an acyclic SNOMED-CT Graph database is created, graph computations such as 
shortest paths and common ancestor queries can be performed rapidly. This is beneficial since 
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be too specific for machine learning analysis. In this study, all nodes are assigned a depth level 
according to the minimum number of edges that must be traversed to reach the root node. The root 
node is at depth level 0. All the mapped SNOMED-CT concepts can then be generalized to 
concepts at a higher depth level [6]. It is important to choose an appropriate depth level to 
accurately distinguish patient characteristics from one another. For medications and diagnosis, a 
depth level of 2 is chosen. A depth level of 3 is chosen for laboratories, since assigning lower depth 
levels returned concepts that are too general [6].  On the other hand, because procedure terms can 
describe a whole spectrum of clinical terminologies and are mapped to SNOMED-CT via multiple 
source vocabularies, concept generalization is not performed, and mapping results are reserved for 
expert evaluation to ensure coverage and accuracy. For a given SNOMED-CT concept, Neo4j can 
quickly calculate all possible paths to the root node. With the Cypher query language, Neo4j 
returns all nodes for a given depth level that are crossed from all possible paths to the root of the 
hierarchy. After converting all SNOMED-CT concepts mapped from laboratory, medication, and 
diagnosis, concepts that are too general and do not provide key information in characterizing 
patients are removed. Examples include “Disorder of body system (362965005)”, “Measurement 
procedure (122869004)”, “Chemical procedure (83762000)”, and “Types of drugs (278471000)”. 
4.2.5 Running Time Analysis 
A running time analysis of the automated mapping pipeline is performed. Since the pipeline is 
composed of multiple steps utilizing multiple algorithms, the running time varies with input 
parameters. However, it can be shown that the entire process scales linearly with the number of 
input vocabularies. In addition, we empirically analyze the scaling behavior of the pipeline by 
conducting several computational experiments. 
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 The most time-consuming step of the mapping pipeline is Metamap’s natural language 
processing step during which the input text undergoes a lexical/syntactic analysis consisting of 1) 
tokenization, 2) part-of-speech (POS) tagging, 3) lexical lookup of words in SPECIALIST lexicon, 
and 4) identification of phrases and lexical heads by the SPECIALIST parser (26). Each phrase 
found by this analysis is further analyzed by 5) variant generation, 6) candidate identification, and 
7) mapping construction (26). 
 Let n be the number of input vocabularies / phrases. The asymptotic computational 
complexity of each step of the analysis is given below: 
 1) The tokenization module uses a regular expression-based approach which needs O(n) 
time (27); 
 2) POS tagging is implemented with the Viterbi Algorithm (28), which uses a bigram 
Hidden Markov Model with 60 possible states corresponding to the POS tags (29).  The asymptotic 
complexity of the Viterbi Algorithm is O(n|V|2) (28), where V=60 — the number of possible POS 
tags; 
 3) The lexical lookup is a simple dictionary lookup process which takes O(n) time; 
 4) Identification of phrases and lexical heads also takes O(n) time; 
 5) Variant generation takes O(mn) time, where m is the number of words in the lexicon 
(27); 
 6) Candidate retrieval is dependent of the number of variants generated in the previous step.  
This step consists of a) tokenization of the variants and b) lexical lookup for the first canonical-
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form token. Both steps use O(k) time, where k is the number of variants generated.  Therefore, 
candidate retrieval takes a total of O(nk) time; 
 7) The mapping construction step evaluates each candidate and generates a Matchmap (27).  
This step uses O(cn) time, where c is the number of candidates retrieved in the previous step. 
 Since V, m, k, and c can all be considered as constants, and each step above scales linearly 
with the number of input vocabularies n, the total running time of Metamap processing uses linear 
time O(n). Remaining steps of the mapping pipeline involves selecting the concept type filtering, 
source vocabulary matching, and filtering, each of which also uses linear time O(n). Thus, the 
entire mapping pipeline has an asymptotic runtime complexity of O(n). 
 To demonstrate the efficiency of the mapping pipeline, computational experiments are 
conducted as follows: the pipeline was implemented and executed using Python 3.6.8 on a Red 
Hat Enterprise Linux 7.3 (Maipo) Server with 8 GenuineIntel Intel Xeon E3-12xx v2 (Ivy Bridge, 
IBRS) processors. 15,000 unique phrases were extracted from the database, with 5,000 related to 
each of medication, laboratory, and procedure (corresponding to CPT code). The mapping pipeline 
was executed for each category of phrases using incrementing subsets of 1000, 2000, 3000, 4000, 
and 5000 and the CPU times are recorded for each subset. Since mapping for diagnosis codes can 
be achieved without the Metamap processing step, they are not included in the experiments. Table 
4.1 compares the CPU time of each set of experiments. It is evident that the processing time 
increases linearly with the number of input phrases within each category with notable overhead. 
Mapping of each input phrase takes on average between 1-1.6 seconds. Thus, the mapping pipeline 
is highly efficient and scales linearly with the number of input phrases. 
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TABLE 4.1. RUNTIME OF MAPPING PIPELINE FOR MEDICATION, LABORATORY, AND 
PROCEDURE PHRASES IN CPU-SECONDS. 
 CPU Time (seconds) 
Number of Input Phrases Medication Laboratory Procedure 
1000 1101.10 1297.99 1285.66 
2000 2033.56 2356.91 2227.67 
3000 3028.25 3346.80 3329.89 
4000 4034.20 4660.72 4375.34 
5000 5000.90 5626.45 5349.73 
 
4.3 RESULTS 
Free text entries from laboratories, medications and ICD9 codes are all successfully mapped to 
SNOMED-CT concepts. Of the 803 unique lab phrases in the CCI-health database, 603 can be 
linked to SNOMED-CT; this covers 1.20 million of 1.33 million patients. Similar successes are 
found for concept mapping of medications, procedures, and diagnoses: 5,899 of 9,755 medication 
phrases are mapped to SNOMED-CT; this covers 801,025 of 952,729 patients. 7,609 of 11,374 
procedure codes are mapped to SNOMED-CT; this covers 1,793,973 of the 1,894,333 patients. 
10,655 of 29,371 ICD-9 codes are linked to SNOMED-CT concepts. Specifically, 2.35 million of 
2.46 million patients contain at least one ICD-9 diagnosis code that can be mapped to SNOMED-
CT. Table 4.2 shows examples of medical entries for medications, laboratories, diagnoses, and 
procedures and their mapped SNOMED concepts. Medications can have many brand names and a 
range of ingredients. Laboratory and procedures may also be described by physicians with a great 
deal of variations. Table 4.3 shows how variations and ambiguity among phrases are eliminated 
by our mapping algorithm. 
TABLE 4.2. MEDICATION, LABORATORY, PROCEDURE, AND DIAGNOSIS PHRASES TO SNOMED 
CONCEPT MAPPING. 
Entity type Entry SNOMED concept SNOMED code 
Medication Mucinex D Tablets Extended Release 
Pseudoephedrine (product) 
91435002 




TABLE 4.2 continued 
Medication Lortab Tablets Acetaminophen 
(product) 
90332006 
 Medication Roxicet Tablets 
Medication Hydrocortisone Acetate Hydrocortisone 
preparation (product) 
16602005 
 Medication Proctofoam Hc Aerosol 




 Lab lipid-vldl-cholesterol 




 Lab urine-creatinine-random 
Lab glucose tolerance test (3 hr) Glucose tolerance test 
(procedure) 
113076002 
 Lab glucose-tolerance-test-5-hour 
Procedure 
Removal of abdominal lining, uterus, both ovaries and 




108188006 Removal of prosthetic material or mesh, abdominal wall for 
infection (eg, for chronic or recurrent mesh infection or 
necrotizing soft tissue infection) (List separately in addition 
to code for primary procedure) 
Procedure 
Re-exploration of liver wound with removal of packing 
Exploration of liver 
(procedure) 
265437009 Exploration of hepatic wound with coagulation and packing 
of liver 
Procedure 
Fecal blood scrn immunoassay Immunoassay method 
(procedure) 
414464004 
Analysis of substance using immunoassay technique 
Diagnosis 
V13.64  Personal history of (corrected) congenital 




V13.65  Personal history of (corrected) congenital 
malformations of heart and circulatory system 
Diagnosis 
770.86  Aspiration of postnatal stomach contents with 




770.14  Aspiration of clear amniotic fluid with respiratory 
symptoms 
Diagnosis 
806.35  Open fracture of T7-T12 level with unspecified 




806.11  Open fracture of C1-C4 level with complete lesion 
of cord 
 
TABLE 4.3. MEDICATION, LABORATORY AND DIAGNOSIS SNOMED DEPTH LEVEL MAPPING. 












Medication Risperidone (product) 108386000 52970 




Medication Amoxicillin (product) 27658006 64842 




Medication Benazepril (product) 108572003 98706 
Lab 
Urine screening for 
protein (procedure) 
171247004 






TABLE 4.3 continued 
Lab 
Measurement of fasting 
glucose in urine specimen 
using dipstick (procedure) 
442033004   2799670 
Lab 


































Hemorrhage of rectum 
and anus (disorder) 











contusion of liver without 





Acute bronchiolitis due to 
respiratory syncytial virus 
(disorder) 
195739001 










In this chapter, interoperability among EHRs from 737 clinical facilities is established using a 
mapping process that disambiguates free text entries. The process provides a unique way to link 
to structured medical concepts despite the extreme variations that can occur during clinical 
diagnosis and documentation. It enables more powerful systems to be developed for future studies 
where semantic distances can be calculated between patient records due to their association with 
hierarchical concepts [6]. The graph database allows for rapid data access and queries. The 
automation of the mapping pipeline allows for easy adaptation to other EHR systems after 
providing minimal user input. Most importantly, this mapping system can be effectively applied 
in clinical big data analytics. It improves the efficiency and discriminatory power of existing 
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machine learning algorithms and allows them to extract useful knowledge from clinical data that 
facilitate the design and implementation of optimized evidenced based treatment plans. Data 
interoperability established via the mapping system can also facilitate the design of universal 
clinical guidelines and rapid knowledge dissemination.  
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5. CHAPTER V 
CHARACTERIZING PATIENT TREATMENT OUTCOMES BASED ON 
LONGITUDINAL DATA 
5.1 INTRODUCTION 
Pattern recognition from longitudinal time series data is important in many domains. In the clinical 
setting, time series data are generated during the delivery of care and exhibit characteristics such 
as irregular sampling rate and unequal lengths. These include laboratory measurements, vital signs, 
and prescription dosages, and are extremely valuable because they track the long-term progression 
of the development of disease. The scale and length of time-series varies a lot because different 
patients have different syndromes [146]. One technique for pattern recognition is transforming 
continuous time-series data into discrete form and using feature extraction. Zhao et al. uses each 
clinical events' temporal weight to create features, which can be used as classifiers [147]. In [146], 
Zhao et al. applied machine learning algorithms to transform longitudinal time-stamped clinical 
data to tabular format and a subsequence-based method to detect adverse drug events using clinical 
measurements. In another study, Yuan et al. proposed an end-to-end model, Wave2Vec, which 
combines deep learning and NLP to learn inherent and temporal signals without requiring any 
expert medical knowledge [148]. The model was applied to two clinical datasets to improve 
interpretability of time series data. These studies demonstrate that discrete features can be 
extracted from time series and used to uncover patterns that lie within these longitudinal data. 
 Clustering analysis is another effective approach for pattern detection from time series data. 
Three main categories of approaches are used to cluster time series data [149]. The first approach 
is to convert time series into simple objects and apply conventional clustering algorithms on these 
objects. For example, one possible method is to shrink the time series to a single point, which is 
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assigned with some analytical value of raw data points [150]. The second approach is to customize 
existing clustering algorithms so that they are applicable to the unconventional time series data. 
Usually, distance metrics for these clustering algorithms need to be modified. For example, 
dynamic time warping (DTW) distance and edit distance are two common shape-based distance 
metrics that can be used in these modified algorithms [78, 83]. Policker et al. applied fuzzy 
clustering methods to estimate the drift in the time series distribution and interpret the resulting 
matrix as weight in a time varying, mixture probability distribution function [151]. The model 
Policker et al. built has the capability of describing the changes in continuous time series more 
naturally and accurately [151]. The third approach is to use multi-step clustering with inputs 
extracted from the multiple dimensions of time series. In [152], time series are clustered in two 
steps–first grouped based on similarity in time, then further grouped based on shape similarity. 
 Discovering patterns from clinical time series is essential for early detection of illness, 
characterization of the severity of chronic conditions, and monitoring patient’s recovery process. 
However, longitudinal clinical data are vastly underused due to the challenges involved in 
analyzing irregular time series. Past studies have attempted to capture trends from time series data 
using predefined features combined with a Gaussian mixture model for clustering episodes from 
the MIMIC II database [153]. It shows success in “search by example” task but heavily relies on 
the manufactured features. In another study, patterns and features are drawn from physiological 
time series data using an unsupervised approach which converts continuous values to discrete 
symbols and builds “bag-of-words” representations of time series [154]. A more recent work 
leverages a switching latent “topic” to construct informative features to rich and heterogeneous 
data generated in the ICUs [155]. These studies all have shown relative successes in pattern 
recognition from clinical time series data, but they rely on the availability of complete, high-
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frequency bedside data, which are not often available in the case of laboratory measurements and 
vital signs. 
 In this chapter, several distance (similarity) metrics and clustering methods are leveraged 
in analysis of sparse, irregular clinical laboratory measurement time series data. A new approach 
is developed to cluster irregular (with unequal lengths and uneven intervals) Multivariate Time 
Series (MTS). In this chapter, the goal is to use these laboratory measurement data to characterize 
treatment outcomes. 
5.2 MATERIAL AND METHODS 
5.2.1 Distance Metrics and Clustering Methods for Univariate Time Series Data 
For univariate clinical laboratory time series, this thesis experiments with DTW [78], Time Warp 
Edit Distance (TWED) [76], and a zero-padding periodogram discrepancy statistic (ZPDS) [156] 
similarity metrics. DTW is a shape-based distance metric which can be effective in detecting the 
different trends of time series. TWED benefits from the triangular inequality property and can 
match time series with time shifting tolerance. Consequently, both DTW and TWED are used to 
detect the change or trend in patient laboratory measurements overtime. In addition, both are elastic 
measures, meaning that they can be applied to time series with unequal length and uneven intervals. 
 Let {xt, t = 1, … , nx} and {yt, t = 1, … , ny} be two time series of different sizes. Without 
loss of generality, assume that nx > ny, we extend the shorter series by adding zeros and getting a 
new series y′t. The ZPDS similarity metric between these two time series is defined by 
𝐝𝐙𝐏(𝐱, 𝐲) = √
𝟏
𝒎𝒙







Where Px(ωj)  and Py′(ωj)  are the periodograms of series xt , and y′t , respectively. The 











Where ωj = 2πj/nx, for j = 1, … , mx, with mx = [nx/2], the largest integer less or equal to nx/2. 
[156]. 
 To cluster time series data based on these metrics, hierarchical or medoid-based clustering 
algorithms should be applied because it is difficult to determine the length of the cluster centers 
when using partition-based clustering algorithms such as K-means [87]. In this chapter, 
agglomerative clustering [157] and K-medoids [158] clustering algorithm are applied on the 
pairwise distance matrix calculated using TWED and ZPDS metrics. Pre-processing techniques 
including resampling and interpolation methods are also leveraged to transform time series so that 
conventional K-means algorithm can be applied. 
5.2.2 Distance Metrics and Clustering Methods for Multivariate Time Series Data  
This thesis proposes a novel clustering approach for irregular MTS based on existing distance 
metrics for variable-length time series. DTW, soft-DTW, and GAK can be used to calculate the 
pairwise distances between variable-length univariate time series. An aggregation function is then 
applied to the distance between all pairs of corresponding univariate time series composing the 
MTS. This produces a pairwise distance matrix representing the similarity between each pair of 
patients. GAK [84] can be used to quantify the similarity between two time series of variable 
lengths. It is positive definite, fast to compute, and operates on the whole spectrum of costs of 
alignments and thus contains a richer statistic than DTW, which considers only the minimum of 
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the set of costs [84]. GAK distance is equal to the sum of the exponentiated and sign changed 
similarities of every alignment pairs: 







where A(n, m) is the set of all possible alignments between two series of length n and m, and any 













κ is a positive definite kernel function, and the Gaussian Kernel is used. Distance between each 
pair of MTS is then calculated by applying an aggregation function on the GAK distance between 
each pair of corresponding univariate time series. Here, we aggregate the distances using the 












𝟐)𝐦𝐭=𝟏 . (4) 
 Alternatively, weighted average, median, or the sum function could be used as the 
aggregation function depending on which laboratory time series is (are) more important. The 
aggregated distance represents an alignment score over each pair of univariate time series and 
provides a holistic similarity measure for the pair of MTS. In the case where patients are 
characterized by different types of laboratory time series, the intersection of these laboratory 
measurements should be selected to form MTSs consisting of the same number of laboratory time 
series. 
 Similar to univariate time series data, K-medoids clustering is applied on the pairwise 





5.3.1 Clustering Patients with Diabetes Using Glycated Hemoglobin (HbA1c) Lab 
Measurements 
The CCI-health database contains 267,666 diabetic patients. For each patient, treatment duration 
is determined by calculating the elapsed time between diagnosis (indicated by the first prescription 
of a diabetic medication) and the last recorded activity (i.e. procedure, laboratory, etc.). To 
characterize treatment outcome quality for these diabetic patients, Glycated hemoglobin (HbA1c) 
lab measurement recorded throughout the treatment duration are used as indicators of treatment 
outcome. In this analysis, only patients with 7 or more HbA1c measurements recorded are included 
in the dataset. This resulted in a total of 3,875 patients. A sliding window with a size of five is 
performed on each patient’s HbA1c measurements, to reduce the noise in the time series. The 
3,875 patients are clustered into two outcome groups based on their smoothed HbA1c lab 
measurement series. Distances between each pair of time series is calculated using the ZPDS 
metric. Finally, agglomerative clustering with average linkage is applied to the calculated pairwise 
distance matrix to cluster these patients into two groups. As a result, 3,475 patients are clustered 
into the “good outcome” group, and the remaining 400 patients are clustered in the “medium 
outcome” group. The outcome quality of the two groups are characterized as “good” versus 
“medium” based on the overall trend of HbA1c lab measurements in each group (Figure 5.1). It is 





Figure 5.1. Agglomerative clustering with ZPDS distance for patients with diabetes based on HbA1c 
measurements. 
5.3.2 Clustering Prostate Cancer Patients Using PSA Measurements 
After all available PSA measurements are retrieved from the EPIC EHR, each patient’s PSA time 
series is resampled to quarterly frequency (one measurement every three months). Gaps in the data 
are filled by propagating the non-NaN values forward first, and then backward along a series. This 
interpolation approach assumes that patients are expected to take new measurements when some 
progress during the treatment process are expected. Patients with very few (<5) measurements 
after resampling are removed from the dataset, resulting in a dataset containing 1,296 patients. The 
pairwise distance matrix is calculated using the TWED distance metrics, and K-medoids is applied 
to cluster these patients into three groups using the distance matrix. Figure 5.2 shows the PSA 
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values over the resampled periods for each of the three resulting patient clusters. The three clusters 
represent “Good”, “Worse”, and “Medium” outcome, respectively. It is notable that in the “Good” 
outcome group, the majority of patients’ PSA measurements are consistently dropping (showing 
that the machine’s concept of good outcome reflects the clinical criteria), whereas the majority of 
the PSA measurements of patients in the “Worse” outcome are either rising or fluctuating within 
a high range. The “Medium” outcome group are characterized by PSA values that are fluctuating 
within a medium to low range but relatively consistent when compared to the “Worse” outcome 
group. 
 





5.3.3 Clustering Patients with Chronic Kidney Disease Using eGFR Measurements 
After extracting all eGFR measurements from the EPIC EHR, the distribution of the duration 
between first and last eGFR measurements for the entire patient cohort is examined. The longest 
duration lasted for 125 months while on average, patients’ screening and treatment process lasted 
for about 120 months. eGFR measurements are resampled to a monthly frequency and linear 
interpolation is applied to fill in missing values. The first 120 data points are sampled from each 
patient’s interpolated lab records so that each time series is equal in length. This sample period 
covers the treatment duration of most CKD patients. K-means algorithm with the Euclidean 





Figure 5.3. K-means clustering with Euclidean distance for patients with CKD based on eGFR 
measurements. 
 Figure 5.3 shows the eGFR values over the sampled 120 months for each of the three 
resulting patient clusters. The three clusters represent “Medium”, “Best”, and “Worst” treatment 
outcome, respectively. These outcomes are defined based on how fast eGFR declines, which 
represent the rate the patient loses his or her kidney function. It is evident that these three patient 
clusters differ in both the rate of eGFR decline and the ending eGFR levels (Table 5.1). 
TABLE 5.1. RATE OF EGFR DECLINE AND ENDING LEVELS BY PATIENT CLUSTERS. 
 eGFR decline rate eGFR ending level 
“Medium” outcome Medium Medium 
“Best” outcome Slow High 




5.3.4 Clustering Patients with Cardiovascular Disease Using Multiple Laboratory 
Measurements 
The CCI-health database [6] contains 37,742 patients with CVD from 737 clinical sites. After pre-
processing, each patient is characterized by 11 raw features including demographics, treatment 
duration, and co-existing conditions, and 1,757 standardized features in SNOMED-CT 
terminology including laboratory tests, diagnosed problems, and medications. For each patient, 
treatment duration is determined by calculating the elapsed time between diagnosis (indicated by 
the first prescription of a medication) and the last recorded activity (i.e. procedure, lab, etc.). 
Measurements of lipids and lipoproteins are processed into time series, since these are closely 
related to cardiovascular conditions and can potentially be used to characterize the severity of CVD. 
Lack of high-density lipoproteins (HDL) is significantly associated with the development of 
coronary heart disease [159]. In contrast, low-density lipoprotein increases the risk of heart disease 
and is considered a “bad” cholesterol [159]. Triglycerides are also associated with incidence of 
heart disease but has a less significant effect [159]. They are not directly atherogenic but represent 
an important marker of CVD risk [160]. 
 In the analysis, HDL, LDL, and Triglycerides measurements are combined to form an MTS 
containing three time series for each patient used for clustering. Each of these time series are 
resampled to quarterly frequency. Gaps in the data are filled by propagating the non-NaN values 
forward first, and then backward. For each of the three types of laboratory measurements, patients 
with less than 3 measurements after resampling from the dataset are removed. This produces a 
dataset containing 450 remaining patients. The GAK distance between each pair of corresponding 
time series is calculated. The pairwise distance between each pair of MTS is then obtained by 
averaging the three distances for each pair of corresponding univariate time series. K-medoids 
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clustering is performed on the final distance matrix, partitioning the patients into three groups. The 
quality of clusters is evaluated both visually and quantitatively. Visually, trends of laboratory 
measurements are shown with boxplots of each patient’s measurement taken at each time point. 
Quantitatively, the following statistics are calculated for each cluster: 1) median of first measured 
value; 2) median of the last measured value; 3) difference between the two medians. Since the goal 
is to segregate patients with different treatment outcomes, ideal clusters of patients should exhibit 
different trends of lab measurements. The three clusters of patients are characterized as having 
“Good”, “Medium”, and “Worse” outcomes by comparing the trends of laboratory measurements 
based on the visualizations and their three summary statistics. 
  
Figure 5.4. Boxplots of HDL laboratory records at each time point by cluster. 
 Figure 5.4, Figure 5.5, and Figure 5.6 show the boxplots of HDL, LDL, and Triglycerides 
laboratory records at each timepoint by cluster. Table 5.2 shows the summary statistics for each 
Good Outcome Worse Outcome Medium Outcome 
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laboratory measurement by cluster. The good outcome cluster shows an upward trend in HDL and 
downward trends in both LDL and Triglycerides (based on visualizations). It also has the largest 
decrease in median values from the first to the last measurement for both LDL and Triglycerides 
(based on summary statistics). The worse outcome group shows a downward trend in HDL and an 
upward trend in Triglycerides (based on visualizations) and has the largest increase in median 
values from the first to the last measurement for Triglycerides (based on summary statistics). 
 
Figure 5.5. Boxplots of LDL laboratory records at each time point by cluster. 




Figure 5.6. Boxplots of Triglycerides laboratory records at each time point by cluster. 
TABLE 5.2. SUMMARY STATISTICS BY CLUSTER 
 Median of HDL LDL Triglycerides 
Cluster 1 
(Good Outcome) 
First Value 44.6 96 130.5 
Last Value 45 86.5 125.5 
Difference 0.4 -9.5 -5 
     
Cluster 2 
(Worse Outcome) 
First Value 42 97 132 
Last Value 43 93 156 
Difference 1 -4 24 
     
Cluster 3 
(Medium Outcome) 
First Value 47 88 112 
Last Value 47 82 113 
Difference 0 -6 1 
 
5.4 DISCUSSION 
This chapter uncovers patient subgroups with varying quality of treatment outcomes based on 
longitudinal laboratory records measured during care delivery. Using time-series clustering, 
treatment outcomes of patients with diabetes, prostate cancer, CKD, and CVD are characterized 
based on the trend of HbA1c, PSA, eGFR, and cholesterol-related laboratory measurements, 
Good Outcome Worse Outcome Medium Outcome 
54 
 
respectively. Specifically, agglomerative clustering with ZPDS and K-medoids clustering with 
TWED distance are applied to univariate time series of varying lengths, and K-means clustering 
with Euclidean distance is applied to pre-processed univariate time series of equal lengths. In 
addition, a novel approach to cluster irregular MTS by aggregating the GAK distance measure 
over univariate time series is introduced. This allows us to characterize treatment outcome based 
on multiple laboratory records for each patient from a more holistic perspective. Each of these 
clustering approaches is able to create well-segregated clusters that differ in the trends of 
laboratory records. 
 By comparing these clustering approaches, it is evident that their strengths differ in 
categorizing different types of trends within the time series data. In particular, the ZPDS metric 
can differentiate between stationary and non-stationary processes [156]. TWED, on the other hand, 
can distinguish time series data with different shapes despite their absolute range of values. 
Euclidean distance used in the K-means clustering algorithm excels in segregating time series 
whose values differ greatly in magnitudes. Finally, GAK distance is used to characterize trends 
over multiple time series in the clustering process. Depending on types of disease and laboratory 
measurements, and the goal of clustering, different metrics should be leveraged to achieve the best 
clustering outcome.  
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6. CHAPTER VI 
DISCRIMINATORY ANALYSIS FOR CLINICAL PROCESS AND OUTCOME 
IMPROVEMENT 
6.1 INTRODUCTION 
Some of the causes of deficiencies in healthcare delivery in the United States include misuse of 
limited medical resources and staff time, practice variability across organizations, and the lack of 
best practice and outcome-driven standards. Data-driven healthcare has the potential to 
revolutionize care delivery and reduce costs. A major challenge is that providers must sift through 
and analyze intelligently mountains of disparate data to materialize the substantial gain. Machine 
learning provides a solution to this problem by efficiently establishing relationships between 
multiple features [161]. In the EHR, every patient instance is represented by a set of features. These 
features may be categorical (e.g. which type of drug is prescribed), continuous (e.g. age), or binary 
(e.g. whether a condition is diagnosed). Given certain labels for these patient instances, supervised 
learning models can be trained to predict the correct labels based on input features. 
 Feature, or variable selection methods is the process of fitting a supervised learning model 
using only a subset of features as predictors for an outcome [162]. It reduces model complexity 
and shortens training time, addresses the problem of the “Curse of Dimensionality” [163], avoids 
overfitting [164], and simplifies the model so that researchers and practitioners can interpret the 
results better [162]. Because clinical data are extremely complex and heterogeneous, it is essential 
to determine the appropriate forms of input variables to represent clinical features. For instance, a 
particular prescription can be represented as a binary variable indicating if a patient received the 
prescription, a nominal variable indicating the brand of the drug, or a continuous variable 
indicating the dosage. 
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 By leveraging supervised learning models combined with feature selection, healthcare 
researchers and practitioners can 1) identify small sets of key factors that impact treatment outcome 
and optimize treatment regimen, 2) design personalized treatment tailored to individual patient 
needs, 3) enhance patients’ experiences, and 4) reduce healthcare resources and costs. 
 In chapter V of this thesis, unsupervised learning models are built to identify patient 
subgroups characterized by differing trends of laboratory measurements. Patients in each cluster 
are labeled with a distinct treatment outcome based on numerical and visual analytics. Because 
these labels are discrete, classification models should be leveraged. In this chapter, various feature 
selection and classification models are used to build outcome prediction models. Patient 
demographics, treatment time and frequency, laboratory tests, vitals, co-existing conditions, 
medications, and clinical procedures are included as potential predictors of treatment outcome. 
6.2 MATERIAL AND METHODS 
In this chapter, discriminatory analysis is conducted on patient datasets labeled with varying 
treatment outcomes using various state-of-the-art supervised learning algorithms. The problem of 
class imbalance is addressed by adjusting the cost of misclassification by specifying different 
weights for each class. A customized scoring metric is also developed to select models with the 
highest accuracies across all classes. In addition, model performances are evaluated using the 
confusion matrix. Various feature selection methods are utilized to reduce the dimension of 
datasets and improve model performance and efficiency. The goal is to identify critical risks and 
treatment factors that impact treatment outcome. 
6.2.1 Supervised Learning Models 
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Random Forest, Naïve Bayes, Support Vector Machine, Gradient Boosting, Logistic Regression 
are the main supervised learning models applied to various datasets. XGBoost [165] is also applied 
to classification tasks due to its high scalability for high-volume data. Different cost functions and 
training evaluation metrics are compared for different datasets. Multi-stage classification is 
performed to refine model performance. 
6.2.2 Feature Selection Methods 
Several popular feature selection methods including Randomized Lasso, feature importance score-
based selection, and wrapper-based approaches such as recursive feature elimination [166] are 
applied to various datasets. The Hilbert-Schmidt Independence Criterion Lasso (HSIC Lasso) is 
also explored due to its ability to capture the non-linear relationship between input and output 
[167]. In addition, results from our in-house DAMIP/PSO machine learning framework [107] are 
compared against output from these commercialized algorithms. 
6.2.3 Class-weighted Balanced Accuracy 
In this thesis, a scoring metric for model performance is developed based on the balanced accuracy 
function [168] to address the issue of class imbalance. In the case of binary classification, the 









) , where TP , P , TN , and N  are true positive (the 
proportion of actual positives that are correctly identified as such), actual positives, true negative 
(the proportion of actual negatives that are correctly identified as such), and actual negatives [168]. 
This balanced accuracy scoring function takes into account the accuracy of both classes and 
ensures that a “good” classifier do not take advantage of imbalance classes [168]. In this thesis, a 
metric is developed based on balanced accuracy to further penalize classifiers with uneven 










. In this definition, each per-class 
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accuracy term from the balanced accuracy function is multiplied by the inverse of that class’s 
proportion. It is given the name “class-weighted balanced accuracy”. This function favors 
classifiers that achieves higher accuracies for the smaller class. 
6.3 RESULTS 
6.3.1. Patients with Prostate Cancer 
Patient treatment outcome for the prostate cancer patient cohort is determined by the “disease-free” 
status based on PSA laboratory measurements. A Python script is developed to remove patients 
with less than 5 measured PSA records or without “Prostate Cancer” in their diagnosed problem 
lists. A patient is characterized as “disease-free” by the Python script if the three most recent PSA 
records all fall within the normal PSA range defined by one’s age group (Table 6.1). the 
distribution of patients by outcome class is shown in Table 6.2.  
TABLE 6.1. NORMAL PSA RANGE BY AGE GROUP. 
Age Range Normal PSA Range 
age 49 or younger 0.0–2.5 ng/mL 
age 50 to 59 0.0–3.5 ng/mL 
age 60 to 69 0.0–4.5 ng/mL 
age 70 or older 0.0–6.5 ng/mL 
TABLE 6.2. SUMMARY OF PATIENT OUTCOME GROUP DISTRIBUTIONS. 
Outcome Not Disease-Free Disease-Free 
# of instances 263 1045 
 Classification models are built using the “disease-free” status as the outcome label. A total 
of 10,003 features are used as input features, including age, treatment procedures, diagnoses, labs, 
and medications during the treatment period (defined as the time between diagnosis of prostate 
cancer and the last measured PSA). All features are binary, with “1” representing “had received”, 
and “0” representing “had not received”, except for patient age, which is continuous. Three 
different feature selection methods are compared: HSIC Lasso, Randomized Lasso, and Recursive 
Feature Elimination with ExtraTrees Classifier [169]. Six different classification algorithms 
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including Naive Bayes, Random Forest, Logistic Regression, SVM, Gradient Boosting, and 
ExtraTrees are used. These algorithms are implemented with the Python scikit-learn package [170]. 
Each classification model is trained on 80% of (1,046) patients with 10-fold cross-validation and 
evaluated on 20% hold-out set of (262) patients. The two sets are partitioned using stratified 
random sampling. The confusion matrix is used as evaluation method. Overall, SVM achieves the 
best results when the “class_weight” parameter is set to “balanced” in the sklearn.svm.SVC class. 
The “scoring” parameter is set to “f1_weighted” for evaluation of model performances. These two 
parameter settings adjust for the imbalanced class issue by increasing the impact of the minority 
class. The RandomizedLasso module is used to select 29 discriminatory features including 
“History of PrCA”, “Cancer metastatic to the bone”, “TRANSPERINEAL PLMT NDL/CATHS 
PROSTATE RADJ INSJ” (Brachytherapy), “Zytiga”, “Radiation Therapy”, “Lipid Panel”, “PSA”, 
“Enzalutamide”, “Creatinine”, “Injection Docetaxel”, etc. Confusion matrices are shown in Table 
6.3 and Table 6.4, corresponding to cross-validation and blind prediction results. 
TABLE 6.3. 10-FOLD CROSS-VALIDATION CONFUSION MATRIX (SCORING FUNCTION: 
“F1_WEIGHTED”). 
 Not disease-free Disease-free 
Not disease-free 158 (75.2%) 52 
Disease-free 246 590 (70.6%) 
TABLE 6.4. BLIND PREDICTION CONFUSION MATRIX (SCORING FUNCTION: “F1_WEIGHTED”). 
 Not disease-free Disease-free 
Not disease-free 42 (79.2%) 11 
Disease-free 66 143 (68.4%) 
 
While keeping all training steps, feature selection, and other parameters intact, the weighted-class 
balanced accuracy is also implemented and used as a “scoring” parameter to select the best 
performing model. The SVM model is chosen, which improves the blind prediction accuracy of 
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the disease-free class while keeping the similar accuracy for the not disease-free class (Table 6.5 
and Table 6.6). 
TABLE 6.5. 10-FOLD CROSS-VALIDATION CONFUSION MATRIX (SCORING FUNCTION: “CLASS-
WEIGHTED BALANCED ACCURACY”). 
 Not disease-free Disease-free 
Not disease-free 150 (71.4%) 60 
Disease-free 235 601 (71.9%) 
TABLE 6.6. BLIND PREDICTION CONFUSION MATRIX (SCORING FUNCTION: “CLASS-
WEIGHTED BALANCED ACCURACY”). 
 Not disease-free Disease-free 
Not disease-free 42 (79.2%) 11 
Disease-free 59 150 (71.7%) 
 
To refine these initial results, a second round of machine learning analysis is performed. First, the 
size of patient dataset is reduced by removing patients whose record do not contain the diagnosed 
problem “Malignant neoplasm of prostate”. This new dataset contains 521 disease-free patients 
and 114 not disease-free patients. Additionally, six key treatment features are identified from 
features selected in the initial analysis: Laparoscopic Prostatectomy, CT Scan of Chest, 
Enzalutamide, Brachytherapy, Radiation Therapy, and Zoledronic Acid IVPB. The PSA 
laboratory value corresponding to the closest date before each of these six treatments is used to 
determine the stage of prostate cancer at which the patient was given the treatment. “0” represent 
“had not received treatment”, and “1”, “2”, “3” corresponds to PSA values 0-10, 10-20, and 20 or 
more, respectively. These six new categorical input features are included as input features for each 
classification model. Each classifier is re-trained on 70% of (444) patients with 10-fold cross-
validation and evaluated on 30% hold-out set of (191) patients. The two sets were re-partitioned 
using stratified random sampling. ExtraTrees classifier achieves the best performance, and the 
results are shown in Table 6.7 and Table 6.8. Four of the six newly created treatment features are 
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selected with HSIC Lasso along with 8 other discriminatory features. Further analysis and expert 
knowledge on these treatment features can provide us with insights on the optimal timing of 
treatment. For comparison, the feature selection and classification steps are repeated on this new 
patient dataset without including the six new features. With the same number of features (12) 
selected from the original feature set, the best performing ExtraTrees classifier achieves worse 
cross-validation accuracies for both groups. As for blind prediction, it loses nearly 15% accuracy 
for the not disease-free group, while only improving the disease-free group’s prediction accuracy 
by 4.4% (Table 6.9 and Table 6.10). 
TABLE 6.7. 10-FOLD CROSS-VALIDATION CONFUSION MATRIX WITH NEW TREATMENT 
FEATURES. 
 Not disease-free Disease-free 
Not disease-free 57 (71.3%) 23 
Disease-free 61 303 (83.2%) 
TABLE 6.8. BLIND PREDICTION CONFUSION MATRIX WITH NEW TREATMENT FEATURES. 
 Not disease-free Disease-free 
Not disease-free 29 (85.3%) 5 
Disease-free 36 121 (77.1%) 
TABLE 6.9. 10-FOLD CROSS-VALIDATION CONFUSION MATRIX WITHOUT NEW TREATMENT 
FEATURES. 
 Not disease-free Disease-free 
Not disease-free 55 (68.7%) 25 
Disease-free 79 285 (78.3%) 
TABLE 6.10. BLIND PREDICTION CONFUSION MATRIX WITHOUT NEW TREATMENT FEATURES. 
 Not disease-free Disease-free 
Not disease-free 24 (70.6%) 10 
Disease-free 29 128 (81.5%) 
 
6.3.2. Patients with Diabetes 
Treatment outcome for the 3,875-patient cohort with diabetes is determined by clustering in 
chapter 5. Each patient is characterized by 24 raw features including hospital site, demographics, 
laboratory tests and results, prescriptions, treatment duration, chronic conditions, blood pressure, 
number of visits and visit frequencies, and 2,205 SNOMED-CT general standardized and 
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unambiguous concepts related to diagnosis, medication, and laboratory. These are included as 
input features in the classification models. The goal is to predict these patients’ treatment outcome. 
The dataset is partitioned into a training set and an independent set for blind prediction using 
stratified random sampling. The training set consists of 2,325 patients (60% of the population), 
and the blind prediction set consists of 1,550 patients (40% of the population). Table 6.11 
summarizes the number of patients in each set. 
TABLE 6.11. PARTITIONING OF DIABETES TREATMENT OUTCOME CLUSTERS FOR 
CLASSIFICATION ANALYSIS. 
 10-fold Cross Validation Training Set Blind Prediction Set 










3875 2325 2074 251 1550 1401 149 
 
In the classification analysis, models are first applied to the training set to establish the 
classification rules using 10-fold cross-validation unbiased estimate. The predictive accuracy of 
each classifier is further assessed by applying the rule to the blind prediction set. 
 To demonstrate the effectiveness of standardized clinical terminologies, classification 
models built from two input feature sets are compared: the first set of input features included only 
the 24 raw features; the second set included the additional 2,205 generalized SNOMED-CT 
concepts obtained from terminology mapping. 
 The DAMIP feature selection and classification framework [107] is contrasted with logistic 
regression, naïve Bayes, radial basis function networks (RBFNetwork), Bayes Net, J48 decision 
tree, and sequential minimal optimization (SMO) approaches implemented in Weka 3.6.13. In 
these Weka classifiers, feature selection is performed using the “InfoGainAttributeEval” as the 
Attribute Evaluator and “Ranker” as the Search Method to select at most 200 features. 
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 Table 6.12 contrasts our in-house DAMIP classification results with six Weka classifiers 
using 24 raw features. Uniformly the six classifiers suffer from group imbalance and tend to place 
all patients into the larger “good outcome” group. In contrast, the DAMIP classifier selects 5 
discriminatory features among the 24 and is able to achieve high classification and blind prediction 
accuracies for both groups. (We remark that the commonly used Pap Smear diagnosis test has an 
accuracy of 70%). 
TABLE 6.12. COMPARISON OF DAMIP RESULTS AGAINST OTHER CLASSIFICATION METHODS. 
Classifier Features set 
10-fold Cross Validation 
Accuracy 

















asthma, race, gender, 
age, height, weight, 
patient site, 5 systolic 
blood pressure 
measurements, and 5 
diastolic blood pressure 
measurements 
89.68% 96.87% 30.28% 90.77% 97.14% 30.87% 
Naïve Bayes 87.05% 92.77% 39.84% 87.94% 92.72% 42.95% 
RBFNetwork 88.22% 98.36% 4.38% 89.03% 97.22% 12.08% 
Bayes Net 87.66% 92.96% 43.82% 87.23% 91.86% 43.62% 
J48 89.16% 97.69% 18.73% 90.65% 97.72% 24.16% 
SMO 89.16% 99.42% 4.38% 90.77% 99.64 7.38% 
DAMIP (5 
features) 




80.1% 80.6% 75.1% 81.9% 81.9% 81.3% 
 
TABLE 6.13. COMPARISON OF PREDICTION ACCURACIES WITH ADDITIONAL 2,205 MEDICAL 
TERMINOLOGIES OBTAINED FROM MAPPING. 
Classifier Features set 
10-fold Cross Validation 
Accuracy 














treatment duration, patient 
site (practice), height, 
asthma, visit frequency, 
race, hypertension, 2 
diastolic blood pressure 
measurements, and 191 new 
features from terminology 
mapping 
87.83% 94.07% 36.25% 89.81% 94.93% 41.61% 
Naïve Bayes 74.75% 76.81% 57.77% 75.29% 77.73% 52.35% 
RBFNetwor
k 
88.73% 99.42% 0.40% 90.39% 100.0% 0.00% 
Bayes Net 80.34% 83.37% 55.38% 80.84% 83.73% 53.69% 
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TABLE 6.13. continued 
J48  89.12% 96.62% 27.09% 87.94% 95.07% 20.81% 
SMO 89.25% 96.77% 27.09% 90.52% 97.29% 26.85% 
DAMIP 
treatment duration, visit 
frequency, asthma, + 6 
features from mapping: 
Injection of therapeutic 
agent (procedure), Oral 
form levofloxacin (product),  
Clopidogrel (product). 
Aspirin (product), Nystatin 
(product), and Metformin 
(product) 
88.7% 88.6% 89.5% 87.9% 86.7% 89.7% 
 
Table 6.13 shows classification results after including 2,205 additional features for each patient. 
With these added features, DAMIP improves its prediction accuracies of both the “good outcome” 
group and the “medium outcome” group. It is observed that instead of selecting the “provider site” 
as one of the discriminatory features, DAMIP selects the type of procedures and medications used 
instead. Identifying these features facilitates dissemination of best practice and target treatment 
regime to specific patients among the sites. For the six Weka classifiers, the results improve only 
slightly on the “medium outcome” group. 
6.3.3. Patients with Cardiovascular Disease 
Treatment outcomes of CVD are determined for 450 patients using MTS clustering on their HDL, 
LDL, and Triglycerides laboratory measurements. Table 6.14 shows the distribution of these 
patients by CVD treatment outcome clusters. 
TABLE 6.14. DISTRIBUTION OF PATIENTS WITH CVD BY OUTCOME CLUSTERS. 
# of Patients 138 233 79 
Outcome Good Medium Worse 
Multi-class classification models are built using these three clusters. Among the 1,768 input 
features (1757 generalized SNOMED-CT concepts and 11 raw features), most are binary with “1” 
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representing “had received”, and “0” representing “had not received”. For gender, “1” represents 
male, and “0” represents female. Age and treatment length are the only continuous input features. 
Two feature selection methods are compared: Randomized Lasso and Recursive Feature 
Elimination with Random Forest Classifier [169]. Eight classification algorithms implemented 
with the Python Scikit-learn package [170] including Logistic Regression, SVM, K-nearest 
neighbors, ExtraTrees, Random Forest, Decision Tree, Neural Network, Gradient Boosting, and 
Bernoulli Naïve Bayes are applied to the dataset. Each classifier is trained on 80% of (360) patients 
with 10-fold cross-validation and evaluated on a 20% hold-out set of (90) patients. The two sets 
are partitioned using stratified random sampling. Overall, ExtraTrees classifier achieves the best 
results. Recursive feature elimination with random forest selects 25 discriminatory features 
including treatment length, “surgical pathology procedure (procedure)”, “urine screening 
(procedure)”, “electrocardiogram finding (finding)”, “immunologic procedure (procedure)”, etc. 
Confusion matrices are shown in Table 6.15 and Table 6.16, corresponding to cross-validation and 
blind prediction results.  
TABLE 6.15. 10-FOLD CROSS-VALIDATION CONFUSION MATRIX. 
 Good Medium Worse 
Good 92 (82.9%) 8 11 
Medium 10 165 (88.7%) 11 
Worse 6 16 41 (65.1%) 
TABLE 6.16. BLIND PREDICTION CONFUSION MATRIX. 
 Good Medium Worse 
Good 24 (88.9%) 0 3 
Medium 2 43 (91.5%) 2 
Worse 1 6 9 (56.3%) 
Of the three outcome groups, the classifier achieves high accuracy on both the “medium” and 
“good” outcome groups. The “worse” outcome group has many misclassified examples due to its 
small sample size. However, it is noticeable that many patients from the “worse” outcome group 
are misclassified into the “medium” outcome group. After re-examining the lab records for patients 
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in each cluster, the “medium” and “worse” outcome clusters are combined into one “Not 
Satisfactory” outcome cluster. A second round of classification is then performed using this new 
two-cluster dataset. 
 Each classifier is re-trained on 70% of (315) patients with 10-fold cross-validation and 
evaluated by a 30% hold-out set of (135) patients. The two sets are re-partitioned using stratified 
random sampling. Overall, Random Forest achieves the best results. Randomized Lasso selects 16 
discriminatory features including ‘Benign neoplastic disease (disorder)’, ‘Disorder of lipoprotein 
AND/OR lipid metabolism (disorder)’, ‘Urine screening (procedure)’, age, treatment length, 
‘Chronic disease of immune system (navigational concept)’, ‘Surgical pathology procedure 
(procedure)’, ‘Open wound of trunk (disorder)’, ‘Immunologic procedure (procedure)’, ‘Hormone 
measurement (procedure)’, ‘Chemical categorized structurally (substance)’, ‘Neoplasm by body 
site (disorder)’, ‘Screening finding (finding)’, ‘Inflammatory disorder of head (disorder)’, 
‘Arteriosclerotic vascular disease (disorder)’, and ‘Hematopoietic system finding (finding)’. 
Confusion matrices are shown in Table 6.17 and Table 6.18.  
TABLE 6.17. 10-FOLD CROSS-VALIDATION CONFUSION MATRIX. 
 Good Not Satisfactory 
Good  76 (78.4%) 21 
Not Satisfactory 14  204 (93.6%) 
TABLE 6.18. BLIND PREDICTION CONFUSION MATRIX. 
 Good Not Satisfactory 
Good 35 (85.4%) 6 
Not Satisfactory 9 85 (90.4%) 
Among the 16 selected features, 'Urine screening (procedure)’, ‘Benign neoplastic disease 
(disorder)’, ‘Chronic disease of immune system (navigational concept)’, ‘Surgical pathology 
procedure (procedure)’ are the most significant factors based on two-sample t-tests. Figure 6.1 




Figure 6.1. CVD outcome by four selected features 
Using only these four features alone, above 70% prediction accuracy can be achieved for both 
patient groups (Table 6.19 and Table 6.20). 
TABLE 6.19. 10-FOLD CROSS-VALIDATION RESULTS USING FOUR PRE-SELECTED FEATURES. 
 Worse Satisfactory 
Worse  77 (79.8%) 20 
Satisfactory 64 154 (70.7%) 
TABLE 6.20. BLIND PREDICTION RESULTS USING FOUR PRE-SELECTED FEATURES. 
 Worse Satisfactory 
Worse 33 (80.7%) 8 
Satisfactory 17 77 (81.4%) 
 
6.4 DISCUSSION 
In this chapter, feature selection and classification models are developed to uncover patient and 
practice characteristics that can predict treatment outcome. Three cohorts of patients with prostate 
cancer, diabetes, and CVD respectively, are studied. 
 Treatment outcome for prostate cancer is determined with patients’ most recent PSA 











Chronic disease of immune system
Surgical pathology procedure (CPT code 88302)




accuracies for the two outcome groups with 29 discriminatory features. Constructing more refined 
features indicating the timing (stage) of key treatment features significantly improves model 
performances. Table 6.21 shows the how the four features related to timing of treatment selected 
by HSIC Lasso impacts treatment outcome. It is notable that all four types of treatments result in 
better outcome if given at earlier stages of prostate cancer. Furthermore, Brachytherapy stands out 
as an effective means of treatment for majority of patients. These features provide key insights to 
optimal timing of prostate cancer treatment. However, until the impact of early intervention for 
prostate cancer is fully understood, particularly for patients of older ages, it is necessary to take 
care in choosing between early definitive therapy and active surveillance [171]. 







Stage 1 Stage 2 Stage 3 Total 
Xtandi (Enzalutamide) 
No 83 6 7 18 114 
Yes 509 7 3 2 521 
Brachytherapy 
No 106 2 4 2 114 
Yes 289 188 40 4 521 
CT Scan 
No 65 22 5 22 114 
Yes 457 57 4 3 521 
Zoledronic 
No 89 4 4 17 114 
Yes 511 6 0 4 521 
 Treatment outcome for diabetes is determined by clustering using patients’ HbA1c 
laboratory test results. Compared to other classification models, the DAMIP model is able to select 
a small set of discriminatory features to establish good classification rules. Specially, the DAMIP-
rules can distinguish patients with good outcomes from those with medium outcomes with over 
80% blind predictive accuracy. By including medical concepts obtained from terminology 
mapping, predictive capabilities of classification models are further improved, creating a more 
powerful evidence-based best practice discovery system. The features identified, including 
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treatment duration, frequency, co-existing condition, and type of regimens allow for design of 
“best practice” clinical practice guidelines. 
 Treatment outcome for CVD is determined via clustering using patients’ HDL, LDL, and 
Triglycerides laboratory test results. The ExtraTrees classifier achieves nearly 90% blind 
prediction accuracy for both “Good” and “Medium” outcome groups with 25 features. Although 
the blind prediction accuracy for the “Worse” outcome group is only 56%, most of these patients 
are mis-classified as having “Medium” outcome. By redefining the “Medium” and “Worse” 
outcome groups into one “Not Satisfactory” group, the Random Forest classifier can achieve above 
85% blind prediction accuracy for both the “Good” and “Not Satisfactory” outcome groups using 
only 16 features. 
 The next step is to use the discriminatory features identified and the criteria developed via 
the machine learning framework to design and optimize evidence-based treatment plans for each 
type of disease and to disseminate such knowledge through “rapid learning” across multiple sites. 
The ultimate goal is to increase quality and timeliness of care and maximize outcome and service 
performance of the healthcare system.  
 One limitation of this work is the fact that only a small portion of patients are selected for 
each cohort for discriminatory studies due to missing or low-quality data. Although the resulting 
classification models achieve high prediction accuracies, the discriminatory features can only 
serve as critical treatment or risk factors for this small subset of patients. Further studies should be 
done to better understand the significance of these features for the larger patient population through 




7. CHAPTER VII 
REDUCING HEALTHCARE DISPARITY WITH REMOTE PATIENT 
MONITORING AND TELEHEALTH 
7.1 INTRODUCTION 
With an aging population and the continuous rise of healthcare costs, more affordable and 
accessible care must be explored. Healthcare expenditures in the United States totaled $3.8 trillion 
in 2014 [172], with roughly 90% spent on chronic illness [173]. It was estimated that about half of 
all adults—117 million —suffer from one or more chronic health conditions [174]. Specifically, 
in a 2011 study [175], it was estimated that adults with arthritis, diabetes mellitus, heart disease, 
and hypertension had average out-of-pocket spending of $1,814 per year. Among those with 
combinations of 2 or 3 conditions, average out-of-pocket spending ranged from $1,134 to $1,760. 
This contrasts to $795 per person for the overall population, and $343 for individuals without any 
chronic illness [174]. Reducing the occurrence of chronic conditions and the number of necessary 
healthcare provider visits, and timely access to medical consultations can help to reduce costs and 
improve health. 
7.1.1 Current State of Telemedicine 
The success of telemedicine can be proven through positive testimonies. A pilot trial at Partners 
HealthCare using remote monitoring for patients with congestive heart failure reduced hospital 
readmission by 9% compared to usual care [176]. Another home telehealth program introduced by 
the Veterans Health Administration (VHA) reported high satisfaction levels among 17,025 
participating patients with one or more chronic illnesses [177]. It reduced number of bed days of 
care by 25% and the number of hospital admissions by 19 % compared to usual care [177]. Many 
telemedicine programs have also achieved significant cost savings. Established in 2001, The 
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Florida Initiative in Telehealth and Education (FITE) provided telemedicine clinics supplemented 
by online education for children with diabetes. The program saved $27,860 per year and reduced 
average hospitalizations from 13 to 3.5 per year [178]. A controlled study of eleven nursing homes 
suggests that by fully engaging in telemedicine, a nursing home could achieve a net savings of 
roughly $120,000 per year [179]. Moreover, telemedicine programs have exerted positive 
environmental impact. A study on the telemedicine consultation database at the University of 
California Davis Health System shows a 278-mile per consultation trip, which resulted in a total 
emissions savings of 1969 metric tons of CO2, 50 metric tons of CO, 3.7 metric tons of NOx, and 
5.5 metric tons of volatile organic compounds between July 1996 and December 2013 [180]. 
 While benefits and challenges for telehealth can be generalized to a certain degree 
nationwide, state statistics and trends can also provide much further detail and a more accurate 
understanding. 108 of Georgia’s 159 counties were found to have persistent poor children’s health 
and working age adult health. Compared to the urban area, Rural Georgia has a poorer, sicker, and 
older population, making it a critically important area to the state’s overall health [181]. 201 areas 
in Georgia are designated as health professional shortage areas (HPSAs) for primary care, with an 
estimated underserved population of 1,371,292 among a total population of 2,066,893 [181]. 
Telemedicine programs can serve as great solutions to improving rural health due to their ability 
to cover more areas with fewer medical workforce.  
 Georgia has enacted laws that require services provided via telehealth to be reimbursed if 
the same service would be reimbursed when provided in person. The state has some coverage for 
telemedicine services in Medicaid and in private insurance. However, Georgia still has stringent 
standards for creating the physician-patient relationship in telemedicine encounters [182]. 
Physicians are less likely to offer telemedicine services to states with rural populations who are 
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less lucrative, more time-consuming, and have costly licensure barriers [182]. Rural areas which 
already have least access to health care, will remain the most underserved despite that telemedicine 
was developed to serve them [182]. 
 Because of the health care disparity between Georgia’s rural and urban populations, many 
different organizations and initiatives are starting up movements to help underserved Georgians 
reach better healthcare. A case study from Sustainable Rural Telehealth Innovation prioritizes what 
a practitioner should keep in mind when in the process of implementing telemedicine operations 
[183]. First, it showed the importance of seeking and following up on grants to support telehealth. 
Other considerations are to create independent entities with appropriate local telehealth knowledge, 
to tailor telehealth innovations to emerging needs and available technology options, and to 
facilitate participation within the rural health institution and collaboration with the local 
community and external partners to make the innovation sustainable [183]. 
7.1.2 Current State of Remote Patient Monitoring and Design Opportunities 
A well-designed remote monitoring system (RMS) should be based on affordable technologies 
that are easily adaptable for the needs of patients. They should promote active patient engagement 
towards maintaining health and proper care management. Three key components are deemed 
important in the design of a reliable remote monitoring system. First, RMS need a secure, 
customizable, two-way communication module that allows patients to interact with care providers 
where sensitive private health care information are protected and safeguarded during transmission 
[184, 185]. Second, the system should be easy-to operate that integrates affordable technologies. 
The RMS should be able to adapt new evolving technologies readily without too much overhead. 
Third, it is desirable to include a movement tracking sensor for detecting sudden falls or potential 
health emergencies. While leading technological companies and investigators have been making 
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advances in RMS for patients requiring home care, most current devices lack one of these three 
components. Most of them are targeted towards specific chronic diseases, with a majority tailored 
for patients with cardiovascular disease. Table 7.1 summarizes the current state-of-the-art 
technology and their design platform and functionalities. 
TABLE 7.1. BEST LOW-COST SENSORS, PRICE, AND CHRONIC CONDITIONS MONITORED 
Sensor Chronic Conditions Price 
Weight Gurus Digital Body Fat Scale 
Diabetes, Pain (Arthritis), Heart 
disease, Obesity 
~$40 
Boso-medicus prestige BP Monitor 
Diabetes, Pain (Arthritis), Heart 
disease, Obesity, Stroke 
~$56 
NeuLog™ Spirometer Sensor and 
NeuLog™ WiFi™ Connection Bundle 
Asthma, Obesity 
$153 (sensor) + $214 (WiFi 
connection bundle) 
Accu-Chek Aviva Connect Blood Glucose 
Monitoring System + Test Strips 
Diabetes 
$30 (system) + $190 (100 
test strips) 
Nonin Onyx II 9560 Bluetooth Oximeter Heart disease, Obesity, Stroke $330 
WinHealth Wireless Body Thermometer 
Diabetes, Asthma, Pain (Arthritis), 
Heart disease, Obesity, Stroke 
~$60 
Rapid Response Medical Alarm with auto 
fall detection 




While some of these systems offer diverse functionalities and easy usage and are non-invasive, 
they are in general expensive, lack customization, and have low implementation feasibility in rural 
areas. An ideal system should achieve low cost, high customizability, high security, and high 
compliance through user-friendly design and good mobility. Furthermore, most of the existing 
systems lack movement tracking sensors for emergency situations. Chronic diseases such as heart 
disease, stroke, and arthritis can trigger sudden falls or other critical situations such as 
unconsciousness and inability to move. An RMS with movement and location tracking along with 
a panic button may facilitate immediate response/intervention by physicians/caregivers. It is 
possible patients may not be able to push the panic button. In this case, an auto alert module can 
notify the physicians/caregivers. It can be designed to connect to an emergency phone line like 
monitored home security systems. In this chapter, a prototypical mobile-based RMS that includes 
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three necessary components for effective remote patient monitoring system and chronic disease 
management is designed. The system can 1) measure and securely upload patient vitals through 
affordable and customizable sensors; 2) provide encrypted two-way communication capability 
between patients and physicians; 3) detect patient movements and alert healthcare providers in the 
event of sudden falls or emergency health situations. Our design is built on existing technologies 
for vital measurement sensors and a fall detection sensor. These are modified and integrated into 
a comprehensive system that is usable by patients with multiple conditions. Smartphone is selected 
as the technology platform since it has high penetration rate in the United States (estimated to 
reach 63.5% by 2017 [186]). The system is comprised of three modules: (1) an application for data 
acquisition, processing, and transmission, (2) an adaptable set of sensors for measuring vitals and 
reporting emergency situations, and (3) a secure communication module for remote patient-
physician interactions. The user interface with the RMS is established through an application 
installed on the patient’s smartphone. 
7.1.3 Cost-Benefit Analysis 
In recent years, a number of studies have pointed out return of investment (ROI) from disease 
management programs as a cost saving metric. ROI is a widely recognized financial tool. Its 
interpretation is straightforward and facilitates communication among legislators, Medicaid 
program officials, plan administrators, health care providers and the public. One of the advantages 
of using ROI is that in the analysis, it requires the inclusion of device design and manufacture and 
the disease program startup as well as the ongoing costs. The Center for Technology and Aging 
reported second-year ROIs of 2.88, 2.92, 7.24, and 1.66 respectively from four RMS studies from 
2010-2012 (Table 7.2) [187]. This translates to each dollar invested in RMS yielded at least $2.88, 
$2.92, $7.24, and $1.66 in savings for the respective organizations. The estimated total returns per 
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patient in the first year for these four organizations are $1,761, $9,882, $4,388, and $2,837, 
respectively, as a result of reduced hospital admits and avoidance of home care visits [187]. These 
analyses clearly indicate that by the end of the second year, the benefits from RMS had exceeded 
the costs. In addition, the RMS designed in this chapter aims to reduce unnecessary costs 
associated with monitoring devices while ensuring quality and achieving security and compliance 
purposes. Therefore, it is expected that our overhead and operating costs will be lower than the 
analyses above, resulting in earlier and higher returns of investment. 
TABLE 7.2. SUMMARY OF ROI STUDIES FOR THE FOUR ORGANIZATIONS. 




Centura Health at 
Home 
-Diabetes, COPD, or CHF patients in 
Denver, CO -24/7/365 clinical call center 
linked with RMS utilizing Cardiocom  
-1.5 month average intervention length 
ROI = 2.6 in Year 1, 2.88 
in Year 2 Total 
returns/patient = $1,761 
2,250 
Dignity Health 
-Patients with Class II, III, or IV CHF 
residing in Central California Coast - RMS 
utilizing Philips Telestation  
-6 month average intervention length 
ROI = 0.4 in Year 1, 2.92 
in Year 2 Total 




-California-based patients with COPD and 
other chronic health conditions  
-Utilized low-cost interactive voice response 
monitoring (IVR) system -6 month average 
intervention length 
ROI = 1.3 in Year 1, 7.24 
in Year 2 Total 
returns/patient = 4,388 
268 
Sharp Healthcare 
-San Diego, California-based patients with 
Class II or III CHF that are high utilizers of 
acute care and that have little or no health 
care insurance  
-Utilized Cardiocom Telescale -2.6 month 
average intervention length 
ROI = 1.63 in Year 1, 
1.66 in Year 2 Total 
returns/patient = 2,837 
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 Due to limited generalizability, in this thesis, existing telemedicine challenges particular to 
the rural areas within the state of Georgia are addressed. Specifically, this chapter 1) formulates a 
p-median facility location to set up telemedicine sites to better serve the rural communities; 2) 
completes a prototypical design of a low-cost remote patient monitoring device that supports 
remote care management, secure communication, and monitoring of disease conditions; 3) 
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performs a basic cost analysis for implementation of telehealth services in rural communities in 
Georgia; and 4) provides recommendations for facilitating telehealth services and implementations. 
7.2 MATERIAL AND METHODS 
7.2.1 Optimized Location for Telemedicine Point of Distribution (POD) Facilities  
7.2.1.1 PROBLEM DESCRIPTION AND FORMULATION 
Currently, Georgia is approaching telemedicine is by passively waiting for rural providers to take 
initiative to join a bigger network in order to serve their local patients. However, a more efficient 
strategy is for the Georgia government to integrate a facility-location model that optimizes the 
system by covering all the demand for patients living in rural areas with little to no access to 
specialists. The main network manager (Georgia Partnership for Telehealth, for instance) might 
have different objectives for their system such as minimizing implementation cost, minimizing 
labor cost, minimizing the number of telemedicine facilities in Georgia, or maximizing the quality 
of care. The model described in this study focuses on the goal of minimizing the number of PODs 
while ensuring that the travel distance for patients from their households to a local telemedicine 
POD is small. Potential POD facilities include supermarkets, grocery stores, and churches. To 
model this problem, we follow a similar procedure described in [188]. Instead of discretizing the 
target region into grids, we instead use census tracts, for which the U.S. census bureau produces 
demographic data. Potential locations within each census tract are selected within the 6km-radius 
of its centroid. Let r and l be two arbitrary census tracts. Let k be the total number of census tracts 
in the region. We define following input parameters: 
• d(r,l)_= distance between centroids r and l; 
• dmax= maximum allowed travel distance from each household to its assigned POD location; 
• cl = the capacity of the facility at census tract l; 
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• pr = demand of census tract r. 
Next, we define the following decision variables: 
• yl =1 if facility site at census tract l is selected for setting up a dispensing facility, 0 
otherwise; 
• xrl =1 if the population in census tract r is served by the facility at census tract l, 0 otherwise. 
Finally, the formulation of the problem is given below: 
Minimize  ∑ yl
k
l=1  (1) 
subject to  ∑ yl
k
l=1 ≥ 2  (2) 
d(r, l)xrl ≤ dmaxyl   ∀ l ∈ 1, … , k  (3) 
∑ xrl = 1    ∀ r ∈ 1, … , k
k
l=1   (4) 
∑ xrl
k
r=1 pr ≤  clyl∀ l ∈ 1, … , k (5) 
xrl, yl ∈ {0,1}, Yij ∈ {0,1}  (7) 
The objective function (1) minimizes the number of open POD locations. Constraint (2) ensures 
at least two PODs are set up. Constraint (3) sets the maximum travel capacity for each household. 
Constraint (4) states that each household must be served by exactly one POD facility. Constraint 
(5) ensures that no demand exceeds capacity at any facility. For the simplicity of the model, the 
following assumptions were considered: 
• The cost of acquiring new telemedicine equipment is the same (constant) for every chosen 
facility. This implies that all the facilities will implement the same equipment and will be 
able to cover most basic needs of rural patients (tele-stethoscope, tele-echocardiograms, 
mental health resources, etc.). 
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• There is a budget constraint on how much money from grants is available to purchase 
equipment, so only a certain number of facilities can open. 
7.2.1.2 CASE STUDY 
This chapter investigates the 37 Georgia counties located in the Appalachian region [189]. Due to 
their history of economic underdevelopment, residents of these counties are particularly 
susceptible to chronic disease [189]. Data retrieved include: 1) US counties, census tract data and 
the 2010 census report from Social Explorer [190]; 2) Appalachian population health data and 3) 
physicians workforce data from the 2017 Health Disparities in Appalachia Report [191]; and 3) 
Potential PODs’ names and locations (using the Google Map Places API [192]). The variables in 
the formulation are assigned as follows: 
• Demand: There are a total of 504 census tracts within the 37 Appalachian counties. Each 
census tract is considered as a demand unit. The demand (pr) for each census tract is 
calculated based on the available morbidity information (i.e. physically and mentally 
unhealthy days):  
 pr = population of census tract r * (physically unhealthy days per person per month 
/ 30 + mentally unhealthy days per person per month / 30). 
• Capacity: Here it is assumed that (1) each physician works 240 days per year and sees 18 
patients per day (based on the Medical Group Management Association 2012 report), (2) 
each patient visits the clinic twice per year, and that (3) telemedicine practice would reduce 
patient visit times by 20 percent [193]. Based on this, the capacity of the facility at census 
tract, cl, is calculated as:  
 cl = population of census tract r * (percentage of primary care physicians + 
percentage of mental health providers) * 2160 / 0.8. 
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• Potential POD Facilities: For each census tract, exactly one facility within a 6 km radius 
of the census tract centroid is selected as a potential POD. These facilities can be 
supermarkets, churches, or grocery stores. 
• Distance: The centroid location of each census tract is used to calculate the pairwise 
distance d(r,l) between the census tracts r and l. The Haversine formula is used to calculate 
the pairwise distances given the latitudes and longitudes, and the unit is in kilometers. 
7.2.2 Remote Patient Monitoring Device 
7.2.2.1 TARGET POPULATION, MARKET DIRECTION, AND DESIGN CONCEPT 
Heart disease, stroke, diabetes, arthritis, and cancer are among the most common, costly, but 
preventable of all health problems in the U.S [194]. The target population of our RMS will be 
patients with one or more of these health conditions. Doctors and/or designated health coaches 
may utilize a remote system to monitor health progress, communicate goal planning, and promote 
education. With numerous sensors available today for monitoring health, uploading measurements 
daily to track progress overtime is a simple task. With these sensors installed, the RMS device will 
be especially valuable for patients with easy-to-monitor symptoms. Patients seeking preventive 
care may also benefit from this device. For usability and wide adoption, it is necessary to simplify 
disease monitoring and patient education using a simple operating system. This is especially 
critical for elderly patients since they may not be as familiar with smartphone technologies as the 
general population. Our prototype is designed to be user-friendly for all adult patients. The goal is 
to develop a straightforward system with clean and easy to read display menus. By using a 
smartphone application with straightforward displays and easy navigation, it should be easy for 
patients to learn to use the system, thus ensuring high adoption and compliance.  
7.2.2.2 SENSORS  
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A variety of sensors have been developed for monitoring symptoms associated with various types 
of chronic diseases. Peak flow meter checks levels of breathing efficiency of asthmatic patients on 
a daily basis. Weight scale can monitor fluctuations in weight which could be attributed to disease 
progression. It is also useful for patients on any weight loss regimen. Blood pressure cuffs and 
electrocardiogram device are available for patients with cardiovascular health issues. For diabetic 
patients, glucose monitor can track changes in glucose levels. PT/INR meter measures blood’s 
anti-coagulation level – the time it takes the blood to “clot”. For patients who are likely to fall due 
to heart attack or other health reasons, sensors that measure changes in movement pattern (e.g. 
movement acceleration, changes in height and orientation to the horizontal position) can detect 
sudden falls. Sensor readings can be collected and input into an aggregator system manually, but 
the goal of our prototype is to automatically retrieve sensor measurements via wireless internet or 
Bluetooth. The list of sensors typically used by patients with the most common chronic diseases 
is shown in Table 7.3. 
TABLE 7.3. LIST OF GENERAL SENSORS AND THE CHRONIC CONDITIONS MONITORED. 
Sensor Chronic Conditions 
Scale  Diabetes, Pain (Arthritis), Heart disease, Obesity 
Blood Pressure Monitor 
Diabetes, Pain (Arthritis), Heart disease, Obesity, 
Stroke 
Spirometer Asthma, Obesity 
Glucose Monitor Diabetes 
Heart Monitor Heart disease, Obesity, Stroke 
Body Temperature Monitor 
Diabetes, Asthma, Pain (Arthritis), Heart disease, 
Obesity, Stroke 
Movement Tracking Sensor Pain (Arthritis), Heart disease, Stroke 
 
Many sensors have been incorporated into wearable systems and have become increasingly 
unobtrusive [195]. Movement sensors today are inexpensive, small, and require little power [195]. 
They will be incorporated into our system for monitoring emergency situations such as sudden 
falls. However other sensors can still be too costly and difficult to use, and this reduces the 
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feasibility for deployment in rural areas and adoption/compliance level. Sensors listed in Table 24 
are selected primarily based on financial considerations while ensuring robust quality and easy 
operation. In order to achieve lowest cost in deployment of our RMS, the sensor system is 
personalized for patients according to their individual conditions. 
7.2.2.3 COMMUNICATION MODULE  
The communication module is set up to allow the patient to interact with medical staff remotely. 
By using the webcam on the smartphone, the patient can hold a video conference with the doctor 
rather than traveling to the hospital to ask a simple question or discuss treatment progress face-to-
face. If the patient’s vital signs raise a red flag in the system, a nurse or physician assistant can 
also contact the patient to review medication and goals. One major technical challenge in patient-
physician communication is that rural broadband connectivity costs for services are higher than 
metropolitan rates. However, the communication technologies themselves are much easier to use 
than anticipated. The expansion of 4G and LTE networks in the United States helps solve 
connectivity issues for higher quality video. Unfortunately, due to security concerns, constant or 
even frequent open two-way communication pathways are difficult with current security protocols 
and technology. Hackers and others with malicious intent could easily gain access to sensitive 
healthcare information if such channels were open. Nevertheless, FaceTime, Skype, and Adobe 
Connect had implemented encryption and other security measures. These encryptions (and their 
continued advances) are indispensable for the usage of RMS due to the sensitivity of the 
transmitted data. Our RMS incorporates Skype’s AES-style encryption. Skype-to-Skype calling 
and video calling products ensure that Protected Health Information (PHI) are encrypted and is 
free to use and easily installed on smart mobile devices [196]. 
7.2.2.4 DATA ACQUISITION AND PROCESSING MODULE  
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The TeleCARE system [197] has proven successful in the remote monitoring process for treatment 
of patients with cardiovascular diseases. Our design integrates two of its components into our 
system – the data acquisition module, which is responsible for collecting data from patient’s 
medical devices and sending them for further processing, and the data processing module, which 
is used for receiving measured data from patients and providing analysis and visualization 
according to rules previously individually defined by physicians. In addition, we integrate the 
TeleCARE mobile application, which is designed in a modular manner that allows for extensions 
of devices to connect to the core application itself and provides measurement values. Currently, it 
is implemented on Android OS, offering functionalities such as simple implementation and pairing, 
geo-localization, measurement visualization and data processing. It will also be implemented on 
the iOS platform, and its security measures will be enhanced when transmitting data between 
patient’s devices and physicians. 
7.2.2.5 SMARTPHONE APPLICATION  
To establish a user-friendly and highly mobile system, we implement a smartphone application 
that provides an interface to accessing all these technologies. The application will require 
fingerprint/password access to protect patient identity. It will be implemented on the most 
prevalent Android and iOS platforms. 
7.3 RESULTS 
7.3.1 Solution to Optimized Telemedicine POD Problem 
The AMPL [198] system is used to build the optimization model using the formulation in the 
materials and methods section, and CPLEX for AMPL 12.2 is used to solve the model. Python 
scripts are developed to parse each dataset and calculate the pairwise Haversine distances. The 
generated data are used to prepare the AMPL data file. 
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 When dmax is set to10 km, the optimal solution for the objective function is 126. This 
represent that the minimum of 126 PODs are required to serve the 504 census tracts. When dmax is 
set to 20 km, the number of PODs required reduces to only 35. 
7.3.2 Prototypic Design of Remote Patient Monitoring Device and Return of 
Investment Analysis 
7.3.2.1 PROTOTYPE ARCHITECTURE OF RMS 
Based on the existing sensor technologies, communication tools, and data management 
applications, we integrate and design our system. Figure 7.1 shows the prototype architecture of 
our RMS. Customized sensors for individual patients take vital measurements and upload them to 
both the smartphone application and the secure cloud storage. Patients manage their chronic 
conditions through the smartphone application. Physicians download patient vitals securely 
through the cloud storage. Two-way communication between physicians and patients is achieved 
via Skype’s video conferencing technologies.  
 
Figure 7.1. Main modules of the remote patient monitoring system. 
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The purpose of the design is multi-fold. It is intended to increase the patient’s independence and 
proactivity in his/her own health care management, while facilitating communication when needed 
between patient and physician for intervention. The intelligent communication pathway through 
broadband is used to facilitate communication between the patient, healthcare providers, and other 
third-party providers. These third-party providers include family and support groups, employer 
wellness programs, and pharmaceutical suppliers. In the backend, nurses, doctors, and other care 
managers can work collaboratively to give the patient appropriate feedback and support. 
7.3.2.2 SMARTPHONE MANAGEMENT APPLICATION 
The mobile application is implemented and deployed on the most popular Android and iOS 
platforms found on modern smartphones. At home, the patient logs on securely with unique bio 
ID or username and password to the health self-management application to collect vital sign data 
through sensor devices and manage treatment process. Through the application, the patient can 
receive a personalized healthcare plan, which includes messages from healthcare providers and 
information regarding treatment goals, medications, diet, and physical activities. The patient can 
also access vital history charts and upload additional vital readings to the cloud database. Figure 




Figure 7.2. Main user interface of the smartphone management application. 
Each of the menu functions are explained below. 
• Messages: Users can compose or view messages. The messages sent from the doctor will 
be text-based, and the outgoing messages can be text, audio, or video-based. 
• Upload: Although sensors can be programmed to automatically collect readings and upload 
data to the cloud database, this option allows user to take and upload the vital measurements 
whenever they want. 
• History: History containing charts of the patient’s sensor readings over time can be 
visualized. 
• Doctor: It contains emergency contact information for the hospital. The user can start a 
video conference with their doctor or take photos for quick remote diagnosis, minimizing 
the need for hospital visits. 
• Medications: Users can view medications prescribed and when to take them. Doctors can 
create automatic reminders for patients to take medications on time. 
• Diet: Users can view daily diet plans designed for them. 
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• Sign Out: Signs out and exits the management program. This prevents sensitive medication 
from leaking when Smartphones are unattended. The application will automatically sign 
out after being idle for a while. 
7.3.2.3 ROI ESTIMATION FOR CARE COORDINATION INSTITUTE’S PATIENT COHORT 
To evaluate the feasibility of implementing the RMS designed in this study, an ROI estimation on 
2.7 million patients from the Care Coordination Institute is performed. Among these patients, 
almost 1 million have more than one chronic condition, and more than 0.1 million have more than 
three chronic conditions. Using the technology operation, management, and personnel costs listed 
in Table 7.4, year one ROIs of 0.65, 0.03, 0.19, 0.13, 0.11, 0.3, and 0.57 are calculated respectively 
for patients with incrementing number of chronic conditions (Table 7.5). This analysis shows that 
each dollar invested in RMS for an individual without any chronic conditions is projected to yield 
at least $0.65 in savings ($1.65 net return) in year 1. As anticipated, the savings is also significant 
among patients with chronic diseases. As more patients start to use the RMS service and the 
technology operations become more automatic, we expect ROIs for later years to continue to 
increase. 






Purchase Cost (Per 
Chronic Condition) 







Mean Out-of- Pocket 
Spending 
$100 
$200 base price with 
additional charge on 
certain components 
Estimates based on patient 
population 
$150 
Based on [174, 175] and 
the number of chronic 
conditions: no condition: 
$343; one: $795; two: 
$1,534; three:1,760; four: 
1,814; five: 2,314; six: 
3,815; > seven:4,217 
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TABLE 7.5. ROI ANALYSIS BY NUMBER OF CHRONIC CONDITIONS. 
Number of Chronic 
Conditions 
Mean Out-of-Pocket Spending 
[175] 






0 $343 $407,588,600 0.65 0.82 
1 $795 $7,475,786 0.03 0.82 
2 $1,134 $37,867,817 0.19 0.75 
3 $1,760 $11,414,186 0.13 0.66 
4 $1,814 $1,970,436 0.11 0.63 
5 $2,314 $653,447 0.3 0.71 
6 $3,815 $88,790 0.57 0.82 
 
7.4 DISCUSSION 
In this study, we identified the key benefits and challenges in the field of telemedicine and 
systematically explored its state-of-art in Georgia. Based on existing knowledge and technologies, 
we provided a practical system for expanding telehealth services in the rural communities of 
Georgia by optimizing potential service locations. 
 While telehealth is growing and expanding in a number of positive directions, observations 
of the current system provide many suggestions on what measures can be taken to improve 
telehealth implementation. Hospitals need to implement telehealth through appropriate key 
performance indicators and allocation of necessary resources. Hospitals also need to incorporate 
telehealth as part of their core business because a solid business plan with a positive ROI is critical 
to integrate a telehealth program even though impact on access to care and quality of care is 
important. Providers should be able to more easily offer care to patients in multiple states. 
Telehealth services implemented with well-defined patient inclusion criteria and protocol would 
be cost-effective. An increase in safety and quality concerns has also proven to reinvigorate and 
jumpstart programs which can create a greater focus on being cost-effective. Continued grant 
funding can help appease a lack of a physician buy-in and consequentially expand the number of 
access points and the number of participating healthcare providers within the telemedicine network.  
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 Based on the current challenges associated with funding, primary care, and healthcare 
services in Georgia, the following recommendations are identified to alleviate the situation: 
 (1) Secure additional sources of funding. Between 2010 and 2030, Georgia’s population is 
projected to grow by an additional 4.6 million people [199]. In 2011 almost 40% of Georgia 
hospitals lost money, and 55% Georgia rural hospitals had negative total margins [181]. It is 
therefore extremely important to individual and providers as well as big networks to develop a 
sustainable business model to implement telemedicine as an effective cost-saving strategy by 
reaching out to telemedicine grants. 
 (2) Expand network to address its shortage of primary care providers. One method is to 
recruit and survey additional physicians. The Georgia Volunteer Health Care Program (GVHCP) 
provides sovereign immunity protection to licensed healthcare professionals who volunteer to treat 
uninsured individuals at or below 200% of the federal poverty level [200]. Another solution is to 
increase the flexibility in state licensing regulations so that doctors from states with a higher 
physician-to-patient ratio could provide telemedicine care to patients in states like Georgia.  
 (3) Increase available services. Finally, Georgia’s specific needs demands an expansion in 
the areas of tele-dentistry, high risk OB/Centering pregnancy, division of family & children 
services (DFACS), and school-based telemedicine programs. 
 In this chapter, a prototypic design of a personalized remote patient monitoring system is 
also presented. The design focuses on patients with one or more chronic diseases. Initially, the 
diseases targeted include asthma, diabetes, chronic pain/arthritis, cardiovascular disease, obesity, 
and stroke. Having assessed available monitoring sensors, data management and communication 
technologies, a new system is composed with a smart-phone based management application. RMS 
addresses growing needs of device and disease compatibility, secure two-way communication, as 
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well as affordability and adoption/compliance. In addition to increasing patient involvement in 
their own healthcare, there is a need to increase patient and provider communication. Interaction 
between doctors and their patients can be facilitated at a lower cost via a remote monitoring system 
than attending a face-to-face consultation. Patients can receive timely medical advice using RMS, 
avoiding the unnecessary wait for appointment that may take several days or weeks. While the 
potential benefits of RMS may outweigh the costs, there are some limitations to keep in mind. 
There is a high initial one-time purchase cost and the subsequent maintenance costs as well as the 
cost for training the hospital staff. Even though the overhead cost may be high, it is estimated that 
the system would pay for itself within two years. Doctors will be able to keep track of patients’ 
progress without lengthy and at times delayed consultations. By implementing this system, the 
cost of healthcare, particularly in the area of chronic diseases, will significantly drop. In the 2015 
Institute of Medicine “Transforming Health Care Scheduling and Care, Getting to Now” report 
[201], it was stated that various technologies are emerging with strong potential to improve real-
time access to care, with the promise of totally new ways of scheduling and delivering care and 
gathering information on its utility. Use of digital and social media, telemedicine and telehealth, 
remote monitoring, and related evolving technologies are also well suited for deployment in health 
care practices. Still, their uptake has been relatively limited to date, for such reasons as 
unfamiliarity, system mismatch, and absence of reimbursement. Underlying the geographic and 
physical barriers to access is the reliance of the U.S. health care system on the office visit as the 
default model of care. Our RMS can thereby offer timely alternative care which can be greatly 
beneficial to chronic disease patients. This is particularly true when RMS can encourage proactive 
engagement of the patients in their own healthcare management. The ability to consult remotely 
in a timely manner allows them to maintain a steady health condition between office visits. For 
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the rural population, RMS will relieve the lack-of-access and expertise burdens within the region. 
Overall, there is strong evidence that a remote monitoring system will benefit those with chronic 
diseases. It allows a reduction in personal healthcare costs while increasing overall wellness. 
Doctors would view the system as a useful tool for reducing hospital readmission rates while 
keeping lines of patient communication open. Though our approach is tailored to meet the needs 
of today’s market, we expect the Smartphone-based system will continue to appeal to the growing, 
aging population as an entertaining and motivating way for patients to take charge of their personal 
heath.   
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8. CHAPTER VIII 
CONCLUSION AND FUTURE WORK 
In this dissertation, a systematic analytic pipeline is developed to address the challenges associated 
with big data in healthcare. This pipeline is composed of technologies and innovations related to 
information extraction, data pre-processing, terminology standardization, longitudinal data mining, 
feature selection and supervised learning, and telehealth. Each of these technologies are developed 
fill some of the most important gaps in the current healthcare industry. 
 In chapter 3, a comprehensive information extraction is developed for Electronic Health 
Records. The pipeline organizes data into a structured, machine-readable format which can be 
effectively applied in clinical research studies to generate practical and unbiased insights from a 
holistic perspective. 
 Chapter 4 builds an automated mapping process to map unstructured clinical texts to 
standardized SNOMED-CT concepts. The process establishes interoperability among the 
heterogeneous data systems from multiple health care sites and providers. It significantly reduces 
data dimension and redundancy, thereby addressing the issue of “curse of dimensionality” 
associated with big data. It also has the potential to facilitate the reimbursement process, improve 
clinical decision support, and promote the exchange of information among multiple sites. 
 Chapter 5 explores the vastly under-utilized longitudinal health data. In this chapter, 
various distance metrics and clustering methods for irregular time series data are investigated. 
These methods address some of the most challenging aspects associated with clinical laboratory 
measurement data—sparse, unevenly-spaced, and unequal in length. Furthermore, an approach to 
cluster irregular multivariate time series data is developed. Future works remains in the search of 
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more robust and systematic methods for evaluating the quality of time series clusters. Given the 
complexity of irregular MTS and the difficulty involved in labelling clusters, it is necessary to 
combine effective visualization techniques with quantitative measures to achieve this task. Mining 
these multi-dimensional longitudinal health data is conducive to understanding patient conditions 
from an evolving perspective. It opens new doors to improving clinical outcome assessment, 
prognostic tools, and personalized care.  
 In chapter 6, clinical outcome prediction models are built with various state-of-art 
supervised learning algorithms. Structured and unstructured data are extracted through the 
information extraction pipeline built in chapter 3. Input features are obtained with the automatic 
concept mapping system developed in chapter 4, and treatment outcome is defined by time series 
clustering approaches developed in chapter 5. Feature selection algorithms are leveraged to 
identify small number of critical factors that affect treatment outcome. Classification rules are 
established via machine learning models using these critical factors. These rules facilitate the 
design of practical evidence-based treatment guidelines and optimization of site performance 
through best practice dissemination and knowledge transfer. 
 Chapter 7 identifies and addresses current challenges in health disparity and leverages 
telehealth and remote patient monitoring as practical intervention methods. Specifically, an 
optimization model to set up telehealth point-of-service locations is formulated and solved, and a 
remote patient monitoring system prototype is designed. Using a return of investment cost-benefit 
analysis on a cohort of 2.7 million patients, the feasibility of the system is evaluated. An important 
future task will involve finding the critical value of maximum allowed travel distance that can 
better balance the tradeoff between the number of PODs and the distance. By addressing the 
challenges in the area of telemedicine and expanding its influence, healthcare industries will be 
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able to improve efficiency and timeliness of patient-centered care, serve more patients in need, 
improve rural health by increasing access to care, reducing unnecessary face-to-face visits, and 
reducing costs. 
 The analytic pipeline developed in this thesis has been applied to the 2.7 million patient 
cohort in the CCI-Health database and the EPIC EHR system. It can be adapted to generic EHR 
systems and clinical big data. Future advances will involve 1) exploring more efficient, 
comprehensive, and accurate information extraction approaches, 2) identifying integrating more 
sources of clinical vocabularies into standardized terminology systems, 3) improving the 
efficiency of time series clustering algorithms and developing more rigorous evaluation metrics 
for clinical time series clustering results, 4) understanding the role of various laboratory 
measurements as biomarkers of risk and recovery progress, 5) advancing feature selection and 
supervised learning methods to improve model performance while addressing issues with clinical 
datasets such as imbalanced classes, 6) monitoring health status and performing rapid analytics 
based on existing data to identify the first sign of health risk, 7) implementing practical clinical 
intervention strategies based on learned knowledge from data mining, and 8) promoting patient-
centered pre-disease and behavior intervention. Finally, the velocity of big data makes it 
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